[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 9214
1. Deng G, Li D, Xiao Z, Li C, Yao H, Peng F, Li M, Zhang P, Chen Z: [Comparative proteome analysis of laser capture microdissection for purified primary tumor and lymph node metastatic tumor in human lung squamous carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Dec;34(12):1182-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative proteome analysis of laser capture microdissection for purified primary tumor and lymph node metastatic tumor in human lung squamous carcinoma].
  • OBJECTIVE: To search for lymph node metastasis-associated proteins in human lung squamous carcinoma (hLSC).
  • METHODS: Laser capture microdissection (LCM) was used to purify the target cells from lung primary tumor and matched lymph node metastatic tumor in hLSC.
  • Two-dimensional gel electrophoresis (2-DE) was performed to separate the total proteins of microdissected tumor cells from lung primary tumor and matched lymph node metastatic tumor.
  • PDQuest software was applied to analyze 2-DE images.
  • The expression of Rho-GDIalpha, one of the differential proteins, in the microdissected lung primary tumor cells (LPTC) and matched lymph node metastatic tumor cells (LNMTC) was detected by Western blot.
  • RESULTS: In the present study, 2-DE patterns of microdissected LPTC and LNMTC were established, and 22 differential proteins in the above two tissues were identified, of which 14 were down-regulated in LNMTC and 8 were up-regulated in LNMTC.
  • CONCLUSION: The 22 differential proteins may play some roles in the process of lymph node metastasis in hLSC, and the data provide new clues for metastasis-associated biomarker screen and mechanism of hLSC.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Microdissection / methods. Neoplasm Proteins / biosynthesis. Proteome / metabolism
  • [MeSH-minor] Aged. Amino Acid Sequence. Electrophoresis, Gel, Two-Dimensional / methods. Female. Humans. Lasers. Lymphatic Metastasis. Male. Middle Aged. Molecular Sequence Data. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045912.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


2. Aoyama K, Kamio T, Nishikawa T, Kameoka S: A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes. Jpn J Clin Oncol; 2010 Jul;40(7):613-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
  • OBJECTIVE: Breast cancer is a heterogeneous disease.
  • The aim of this prospective study, in which fluorescence in situ hybridization was used to determine human epidermal growth factor receptor 2 status in primary breast cancers and in the lymph node metastases, was to verify the stability of human epidermal growth factor receptor 2 status in the following steps of neoplastic progression of breast cancer, which is fundamental for an appropriate therapeutic approach.
  • METHODS: From patients with primary breast cancer, for whom, after January 2003, surgery was performed and involved metastatic lymph nodes were found, we randomly selected four groups of 15 patients, whose human epidermal growth factor receptor 2 score by immunohistochemistry was either 0, 1+, 2+ or 3+, respectively, totaling to 60.
  • For each of those patients, their primary tumors and all of the metastatic lymph nodes were examined.
  • Primary tumors and metastatic lymph nodes in each patient were examined by fluorescence in situ hybridization.
  • RESULTS: Of 18 patients with fluorescence in situ hybridization-positive primary tumors, 15 (83.3%) were fluorescence in situ hybridization-positive and 2 (11.1%) were fluorescence in situ hybridization-negative in all of their metastatic lymph nodes, and 1 (5.5%) patient had mixed (fluorescence in situ hybridization-positive or -negative) metastatic lymph nodes.
  • Of 42 patients with fluorescence in situ hybridization-negative primary tumors, 40 (95%) were fluorescence in situ hybridization-negative and 2 (5%) fluorescence in situ hybridization-positive in all of their metastatic lymph nodes.
  • CONCLUSIONS: This study revealed that fluorescence in situ hybridization resulted in a high concordance of 83.3% between the human epidermal growth factor receptor 2 manifestation (fluorescence in situ hybridization-positive status) in primary tumors and that in metastatic lymph nodes, demonstrating that it is appropriate to determine whether and how to apply treatment by trastuzumab based on the results of evaluation of human epidermal growth factor receptor 2 expression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Prospective Studies. Trastuzumab


3. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue-Geile KL: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer; 2010 Mar 16;10:101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
  • Our goal was to develop a high throughput, cost-effective and simple methodology for the detection of clinically relevant hot spot mutations in colon cancer.
  • METHODS: The Maldi-Tof mass spectrometry platform and OncoCarta panel from Sequenom were used to profile 239 colon cancers and 39 metastatic lymph nodes from NSABP clinical trial C-07 utilizing routinely processed FFPET (formalin-fixed paraffin-embedded tissue).
  • RESULTS: Among the 238 common hot-spot cancer mutations in 19 genes interrogated by the OncoCarta panel, mutations were detected in 7 different genes at 26 different nucleotide positions in our colon cancer samples.
  • Further evidence demonstrating the validity of the data was the fact that the mutation frequencies of the most common colon cancer mutations were similar to the COSMIC (Catalog of Somatic Mutations in Cancer) database.
  • In addition, infrequent mutations in NRAS, AKT1, ABL1, and MET were detected.
  • Mutation profiling of metastatic lymph nodes and their corresponding primary tumors showed that they were 89.7% concordant.
  • All mutations found in the lymph nodes were also found in the corresponding primary tumors, but in 4 cases a mutation was present in the primary tumor only.
  • CONCLUSIONS: This study describes a high throughput technology that can be used to interrogate DNAs isolated from routinely processed FFPET and identifies the specific mutations that are common to colon cancer.
  • [MeSH-minor] Alleles. Cost-Benefit Analysis. Genes, ras. Humans. Lymphatic Metastasis. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins B-raf / genetics. Reproducibility of Results. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Metastatic cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Recent Clin Trials. 2007 May;2(2):121-34 [18473997.001]
  • [Cites] Blood. 2008 May 1;111(9):4788-96 [18252861.001]
  • [Cites] Lancet Oncol. 2008 Oct;9(10):962-72 [18804418.001]
  • [Cites] Gut. 2009 Jan;58(1):90-6 [18832519.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1851-7 [19223544.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1477-84 [19237633.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):3021-31 [19318576.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3184-8 [19366826.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1228-9 [11751233.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7025-30 [12460923.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6272-81 [14559814.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26445-52 [15075332.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6063-9 [16024606.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] J Mol Diagn. 2005 Nov;7(5):623-30 [16258161.001]
  • [Cites] Mol Cancer. 2006;5:2 [16403224.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2765-71 [16381005.001]
  • [Cites] Am Surg. 2006 May;72(5):445-53 [16719202.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1318-21 [17330094.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):439-44 [17611497.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2255-9 [18224685.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1582-4 [18316790.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11 [18428421.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5705-12 [19001320.001]
  • (PMID = 20233444.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004931
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2845115
  •  go-up   go-down


Advertisement
4. Wang JF, Dai DQ: [Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer]. Zhonghua Yi Xue Za Zhi; 2006 Feb 28;86(8):536-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer].
  • OBJECTIVE: To investigate the difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer.
  • METHODS: Methylation CpG island amplification (MCA) was used to enrich the methylated DNA sequences in the cancer tissues and lymph nodes with metastatic gastric cancer resected during operation from 5 patients.
  • Representational difference analysis (RDA) was conducted with the MCA products from the lymph nodes with metastatic gastric cancer as testers and the MCA products of the gastric primary cancer as drivers.
  • Hybridization analysis was performed, using the No 1-3 round RDA products and the MCA products of the tissues of gastric primary cancer and lymph nodes with metastatic gastric cancer with digoxin-labeled KL22 fragment as probe.
  • CONCLUSION: There is a difference in DNA methylation between the tissues of primary cancer and lymph nodes with metastatic gastric cancer.
  • PTPRG gene may be a candidate gene for metastasis of gastric cancer.
  • [MeSH-minor] Base Sequence. CpG Islands / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Deoxyribonucleases, Type II Site-Specific / metabolism. Humans. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681882.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.1.21.4 / CCCGGG-specific type II deoxyribonucleases; EC 3.1.21.4 / Deoxyribonucleases, Type II Site-Specific
  •  go-up   go-down


5. Wang L, Zhu JS, Song MQ, Chen GQ, Chen JL: Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray. World J Gastroenterol; 2006 Nov 21;12(43):6949-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray.
  • AIM: To study the differential gene expression profiles of target cells in primary gastric cancer and its metastatic lymph nodes using laser microdissection (LMD) in combination with cDNA microarray.
  • METHODS: Normal gastric tissue samples from 30 healthy individuals, 36 cancer tissue samples from primary gastric carcinoma and lymph node metastasis tissue samples from 58 patients during gastric cancer resection were obtained using LMD in combination with cDNA microarray independently.
  • After P27-based amplification, aRNA from 36 of 58 patients (group 1) with lymph node metastasis and metastatic tissue specimens from the remaining 22 patients (group 2) were applied to cDNA microarray.
  • Semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical assay verified the results of microarray in group 2 and further identified genes differentially expressed in the progression of gastric cancer.
  • The results were confirmed at the level of mRNA and protein, and suggested that four genes (OPCML, RNASE1, YES1 and ACK1) could play a key role in the tumorigenesis and metastasis of gastric cancer.
  • The expression pattern of 3 genes (OPCML, RNASE1 and YES1) was similar to tumor suppressor genes.
  • For example, the expression level of these genes was the highest in normal gastric epithelium, which was decreased in primary carcinoma, and further decreased in metastatic lymph nodes.
  • Four genes were further identified as differentially expressed genes in the majority of the cases in the progression of gastric cancer.
  • CONCLUSION: LMD in combination with cDNA microarray provides a unique support foe the identification of early expression profiles of differential genes and the expression pattern of 3 genes (OPCML, RNASE1 and YES1) associated with the progression of gastric cancer.
  • Further study is needed to reveal the molecular mechanism of lymph node metastasis in patients with gastric cancer.
  • [MeSH-major] Gene Expression Profiling / methods. Lasers. Lymphatic Metastasis / genetics. Microdissection / methods. Oligonucleotide Array Sequence Analysis / methods. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. DNA, Neoplasm / genetics. Disease Progression. Female. GPI-Linked Proteins. Gene Expression Regulation, Neoplastic / genetics. Genes, Neoplasm / genetics. Humans. Male. Middle Aged. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins c-yes / genetics. Proto-Oncogene Proteins c-yes / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Ribonuclease, Pancreatic / genetics. Ribonuclease, Pancreatic / metabolism. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol. 1998 Nov-Dec;7(3-4):183-95 [10677169.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:220-31 [12724227.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15240-8 [11278365.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6163-9 [11507068.001]
  • [Cites] Glia. 2002 Feb;37(2):93-104 [11754208.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):19-24 [11756219.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S39-47 [11821786.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):19-23 [12079294.001]
  • [Cites] Oncology. 2002;63(4):398-404 [12417796.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):337-43 [12819783.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2366-9 [14562415.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):68-75 [15011833.001]
  • [Cites] Nature. 2004 Mar 11;428(6979):194-8 [15014503.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1194-201 [15037588.001]
  • [Cites] Pancreas. 2004 Apr;28(3):353-8 [15084985.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17283-8 [15004027.001]
  • [Cites] Biochim Biophys Acta. 2004 May 3;1691(2-3):105-16 [15110991.001]
  • [Cites] World J Gastroenterol. 2004 May 15;10(10):1425-30 [15133847.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5105-9 [15122318.001]
  • [Cites] J Neurosurg. 2004 Sep;101(3):505-10 [15352609.001]
  • [Cites] Chin Med J (Engl). 2004 Aug;117(8):1210-7 [15361297.001]
  • [Cites] Genes Dev. 1994 Jan;8(1):9-22 [8288131.001]
  • [Cites] Science. 1996 Nov 8;274(5289):998-1001 [8875945.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):63-7 [9212732.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7536-40 [16437730.001]
  • [Cites] Head Neck. 2003 Jan;25(1):44-9 [12478543.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • (PMID = 17109515.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA, Neoplasm; 0 / GPI-Linked Proteins; 0 / OPCML protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Proto-Oncogene Proteins c-yes; EC 2.7.10.2 / TNK2 protein, human; EC 2.7.10.2 / YES1 protein, human; EC 3.1.27.5 / Ribonuclease, Pancreatic
  • [Other-IDs] NLM/ PMC4087337
  •  go-up   go-down


6. Datta K, Muders M, Zhang H, Tindall DJ: Mechanism of lymph node metastasis in prostate cancer. Future Oncol; 2010 May;6(5):823-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of lymph node metastasis in prostate cancer.
  • Detection of lymph node metastases indicates poor prognosis for prostate cancer patients.
  • Therefore, elucidation of the mechanism(s) of lymph node metastasis is important to understand the progression of prostate cancer and also to develop therapeutic interventions.
  • In this article, the known mechanisms for lymph node metastasis are discussed and the involvement of lymphatic vessels in prostate cancer lymph node metastasis is comprehensively summarized.
  • In addition, contradictory findings regarding the importance of lymphangiogenesis in facilitating lymph node metastasis in prostate cancer are pointed out and reconcilation is attempted.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 May;80(3-4):569-78 [10408868.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):309-13 [10390013.001]
  • [Cites] J Cell Physiol. 2005 Jan;202(1):205-14 [15389531.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):193-9 [14716745.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1054-8 [15057248.001]
  • [Cites] J Urol. 2004 Jul;172(1):103-7 [15201747.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4400-4 [15231646.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5137-44 [15297417.001]
  • [Cites] World J Gastroenterol. 2004 Nov 15;10(22):3261-3 [15484296.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):333-45 [15488757.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70 [7724599.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1751 [8612600.001]
  • [Cites] Development. 1996 Dec;122(12):3829-37 [9012504.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 [9435229.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6599-602 [9506953.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):71-80 [9537602.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):385-94 [10027397.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):789-801 [10037799.001]
  • [Cites] Nat Rev Immunol. 2006 Sep;6(9):659-70 [16932751.001]
  • [Cites] BJU Int. 2006 Oct;98(4):903-6 [16978291.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9566-75 [17018613.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6012-7 [17062674.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1164-73 [15734999.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1089-99 [15809353.001]
  • [Cites] J Pathol. 2005 Jun;206(2):170-7 [15846845.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4739-46 [15930292.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4642-8 [15746084.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6901-9 [16061674.001]
  • [Cites] Trends Cell Biol. 2005 Aug;15(8):434-41 [16005628.001]
  • [Cites] EMBO J. 2005 Aug 17;24(16):2885-95 [16052207.001]
  • [Cites] Oncogene. 2005 Aug 18;24(35):5510-20 [15897888.001]
  • [Cites] Prostate. 2005 Oct 1;65(2):110-6 [15880525.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):222-30 [15948136.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9261-8 [16230387.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9789-98 [16267000.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):946-53 [16355212.001]
  • [Cites] Pathol Res Pract. 2006;202(2):93-8 [16413692.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):392-8 [16400321.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):209-23 [16530705.001]
  • [Cites] Blood. 2006 May 1;107(9):3531-6 [16424394.001]
  • [Cites] FASEB J. 2006 Jul;20(9):1462-72 [16816121.001]
  • [Cites] Oncogene. 2006 Aug 17;25(36):4965-74 [16568082.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2406-12 [10590384.001]
  • [Cites] Semin Perinatol. 2000 Feb;24(1):75-8 [10709865.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4324-7 [10969769.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6111-5 [11085535.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):66-73 [11148561.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):672-82 [11179212.001]
  • [Cites] Nat Med. 2001 Feb;7(2):186-91 [11175849.001]
  • [Cites] Nat Med. 2001 Feb;7(2):192-8 [11175850.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1786-90 [11280723.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):462-8 [11297234.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1422-8 [11381041.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 7;93(21):1638-43 [11698568.001]
  • [Cites] Nat Cell Biol. 2002 Jan;4(1):E2-5 [11780131.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1505-13 [11927535.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):434-40 [11950918.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] FASEB J. 2002 Jul;16(9):922-34 [12087053.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1255-7 [12218087.001]
  • [Cites] Dev Cell. 2002 Sep;3(3):411-23 [12361603.001]
  • [Cites] J Exp Med. 2002 Dec 2;196(11):1497-506 [12461084.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1166-71 [12649170.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1747-51 [14534690.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):109-11 [17227994.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):593-9 [17234768.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1010-7 [17032920.001]
  • [Cites] Oncogene. 2007 Mar 15;26(12):1731-8 [16964283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5026-31 [17360402.001]
  • [Cites] FASEB J. 2007 Apr;21(4):1088-98 [17242158.001]
  • [Cites] Oncogene. 2007 May 10;26(21):2997-3005 [17130836.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1748-54 [17570654.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):610-5 [18284936.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):331-42 [18394556.001]
  • [Cites] Cardiovasc Res. 2008 May 1;78(2):315-23 [18065770.001]
  • [Cites] Prostate. 2008 Jul 1;68(10):1057-63 [18386298.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:225-34 [18519975.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):604-17 [18497750.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8770-8 [18974119.001]
  • [Cites] Am J Pathol. 2008 Dec;173(6):1891-901 [18988807.001]
  • [Cites] Cancer Sci. 2009 Jun;100(6):983-9 [19385973.001]
  • [Cites] Eur Urol. 2009 Feb;55(2):261-70 [18838212.001]
  • [Cites] Arch Med Res. 2009 May;40(4):268-75 [19608016.001]
  • [Cites] Eur Urol. 2009 May;55(5):1003-11 [19211184.001]
  • [Cites] Eur Urol. 2009 Jun;55(6):1251-65 [19297079.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6042-8 [19638584.001]
  • [Cites] BJU Int. 2009 Sep;104(5):592-7 [19594740.001]
  • [Cites] Surg Oncol. 2009 Sep;18(3):213-8 [19269808.001]
  • [Cites] Int J Cancer. 2009 Dec 15;125(12):2747-56 [19569051.001]
  • [Cites] BMC Cancer. 2009;9:362 [19821979.001]
  • [Cites] Semin Cancer Biol. 2009 Oct;19(5):285-97 [19482087.001]
  • [Cites] Prostate. 2010 Feb 15;70(3):276-87 [19827050.001]
  • [Cites] Head Neck. 2010 Jun;32(6):786-92 [19890908.001]
  • [Cites] J Surg Res. 2011 May 15;167(2):267-72 [19783007.001]
  • (PMID = 20465393.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 121277; United States / NCI NIH HHS / CA / R01 CA140432; United States / NCI NIH HHS / CA / CA 91956; United States / NCI NIH HHS / CA / CA140432-01A2; United States / NCI NIH HHS / CA / CA 125747; United States / NCI NIH HHS / CA / R01 CA125747; United States / NCI NIH HHS / CA / R01 CA140432-01A2; United States / NCI NIH HHS / CA / CA 140432; United States / NCI NIH HHS / CA / R01 CA121277; United States / NCI NIH HHS / CA / P50 CA091956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 100
  • [Other-IDs] NLM/ NIHMS207617; NLM/ PMC2892838
  •  go-up   go-down


7. Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH: Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thorac Oncol; 2009 Nov;4(11):1307-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival.
  • INTRODUCTION: This study aimed to compare the expression profiles of excision repair crosscomplementation group 1 (ERCC1), x-ray repair crosscomplementation group 1 (XRCC1), and betaIII-tubulin between patients with primary non-small cell lung cancer (NSCLC) and those with metastatic lymph nodes and to identify the prognostic significance of each chemotherapy resistance protein.
  • MATERIALS: Those who met the inclusion criteria were patients (1) with NSCLC, (2) with metastatic lymph nodes (N1 or N2), and (3) who underwent surgical resection followed by platinum-based adjuvant chemotherapy.
  • The expression profile of each protein was evaluated by immunohistochemistry and compared according to tumor location.
  • ERCC1 expression was upregulated in 55% and downregulated in 8% of metastatic lymph nodes, when compared with primary tumors (p < 0.05).
  • betaIII-tubulin expression in metastatic lymph nodes was greater in patients with adenocarcinoma than other cell types.
  • Upregulation of ERCC1 in metastatic lymph nodes was a poor prognostic factor in N1 patients but not in N2 patients.
  • CONCLUSIONS: Significant changes in the expression profile of each protein were observed in metastatic lymph nodes.
  • The resistance protein-guided treatment should be performed after integrative interpretation of expression profiles of each protein in both primary and metastatic sites.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. DNA-Binding Proteins / biosynthesis. Endonucleases / biosynthesis. Lung Neoplasms / metabolism. Lymph Nodes / metabolism. Tubulin / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. DNA Repair. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2010 Aug;5(8):1310-1; author reply 1311 [20661095.001]
  • (PMID = 19745766.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TUBB3 protein, human; 0 / Tubulin; 0 / X-ray repair cross complementing protein 1; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  •  go-up   go-down


8. Pantalone D, Andreoli F, Fusi F, Basile V, Romano G, Giustozzi G, Rigacci L, Alterini R, Monici M: Multispectral imaging autofluorescence microscopy in colonic and gastric cancer metastatic lymph nodes. Clin Gastroenterol Hepatol; 2007 Feb;5(2):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multispectral imaging autofluorescence microscopy in colonic and gastric cancer metastatic lymph nodes.
  • The methods available for the detection of metastatic lymph nodes are numerous.
  • These include lymphoscintigraphy and radiolabeled antibody detection, but in most cancers the currently used technique is sentinel lymph node identification, performed primarily through the use of immunohistochemistry.
  • We propose the application of autofluorescence (AF)-based techniques for lymph node evaluation in colorectal and gastric tumors.
  • Autofluorescence microspectroscopy and multispectral imaging autofluorescence microscopy have been used to analyze the AF emission of metastatic lymph node sections, excited with 365-nm wavelength radiation.
  • Monochrome AF images were acquired sequentially through interference filters peaked at 450, 550, and 650 nm, and then combined together in a single red-green-blue image.
  • The AF pattern and the emission spectrum of metastatic lymph nodes have unique characteristics that can be used to distinguish them from the normal ones.
  • RESULTS: The results, compared with standard histopathologic procedures and with specific staining methods, supplied a satisfactory validation of the proposed technique, revealing the possibility of improving the actual diagnostic procedures for malignant lymph node alterations.
  • CONCLUSIONS: With the development of appropriate instrumentation, the proposed technique could be particularly suitable in intrasurgical diagnosis of metastatic lymph nodes.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Lymphatic Metastasis / diagnosis. Microscopy, Fluorescence. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296531.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Kuga Y, Tanaka T, Arita M, Usui Y, Okanobu H, Numata Y, Miwata T, Yoshimi S, Murakami E, Moriya T, Ohya T, Nishida T: [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1923-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma].
  • We report a case of left inguinal lymph node metastasis of anal canal carcinoma, treated effectively with chemotherapy consisting of S-1 and CDDP combined with radiotherapy.
  • In February 2006, a 76-year-old woman underwent resection of a tumor diagnosed as squamous cell carcinoma of the anal canal.
  • The metastatic tumor in the lymph node responded well to the treatment and decreased remarkably in size by December 2007.
  • After chemoradiotherapy, the oral administration of S-1 alone (80 mg/body) for 2 weeks followed by a 2-week rest period as one course was continued for 1 year.
  • The lymph node metastasis had disappeared 1 year after chemoradiotherapy, as determined by computed tomography (CT) and positron emission tomography-CT, representing a complete response.
  • Chemotherapy consisting of S-1 and CDDP concurrent with radiotherapy maybe effective for treating metastatic lymph node metastasis of anal canal carcinoma.
  • [MeSH-major] Anal Canal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920402.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Imre K, Pinar E, Oncel S, Calli C, Tatar B: Predictors of extracapsular spread in lymph node metastasis. Eur Arch Otorhinolaryngol; 2008 Mar;265(3):337-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of extracapsular spread in lymph node metastasis.
  • We investigated effect of clinical and pathologic parameters on extracapsular spread (ECS) in patients with lymph node metastasis in laryngeal and hypopharyngeal cancer.
  • Relationship between ECS and tumor location, T stage, pathologic N stage, tumor differentiation, number of metastatic lymph nodes, diameter of metastatic lymph node and impact of presence ECS on contralateral neck metastasis (CNM) were evaluated; 76 of the 186 patients had lymph node metastasis.
  • Tumor location, pathologic N stage of the tumor, number of metastatic lymph nodes, diameter of metastatic lymph node and the presence of CNM were significantly associated with ECS (P < 0.05).
  • Only number of (>or=3) lymph node metastasis emerged as significant independent predictor of ECS (P < 0.05; OR:11.6).
  • In conclusion, the number of metastatic lymph nodes (>or=3) should be used as predictor of ECS.
  • Furthermore, contralateral neck dissection should be performed in patients with ipsilateral lymph node metastasis with ECS.
  • [MeSH-minor] Adult. Aged. Female. Humans. Laryngectomy. Logistic Models. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899142.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Zhu Y, Zhang SL, Ye DW, Yao XD, Dai B, Zhang HL, Shen YJ, Zhu YP, Shi GH, Ma CG: Prospectively packaged ilioinguinal lymphadenectomy for penile cancer: the disseminative pattern of lymph node metastasis. J Urol; 2009 May;181(5):2103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospectively packaged ilioinguinal lymphadenectomy for penile cancer: the disseminative pattern of lymph node metastasis.
  • PURPOSE: We prospectively evaluated the disseminative pattern of lymph node metastasis in penile cancer cases using packaged lymphadenectomy.
  • In addition, we analyzed prognostic factors of the extent of lymph node metastasis.
  • A total of 24 patients with 1 or more positive inguinal lymph nodes underwent packaged iliac lymphadenectomy.
  • Inguinal lymphadenectomy was divided into 3 packages, including medial inguinal, lateral inguinal and Cloquet's node packages.
  • Clinicopathological features of the primary tumor and lymph nodes were correlated with the extent of lymph node metastasis.
  • RESULTS: Of 92 groin basins 27 cases of inguinal lymphadenectomy and 7 of iliac lymphadenectomy had lymph node metastasis.
  • No extended lymph node metastasis was observed in the absence of positive lymph nodes in the medial inguinal package.
  • In groin basins with lymph node metastasis in the medial inguinal package extranodal extension was a significant predictor of extended lymph node metastasis.
  • Cloquet's node was associated with iliac lymph node metastasis on univariate analysis.
  • However, it was of limited predictive value in patients with 1 or 2 positive inguinal lymph nodes.
  • CONCLUSIONS: The medial inguinal package defined in our study was the first involved lymph node region in penile cancer cases.
  • Extranodal extension was an important predictor of extended lymph node metastasis beyond the medial inguinal package.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Lymph Node Excision / methods. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Penile Neoplasms / pathology. Penile Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Humans. Immunohistochemistry. Inguinal Canal. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Urogenital Surgical Procedures / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Urol. 2010 Mar;183(3):1261
  • (PMID = 19286211.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Wasif N, Tomlinson JS, Maggard MA, Giuliano AE, Ko CY: Polypectomy or surgery for malignant colonic polyps: Do we need to change the NCCN guidelines? J Clin Oncol; 2009 May 20;27(15_suppl):4031
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypectomy or surgery for malignant colonic polyps: Do we need to change the NCCN guidelines?
  • The National Comprehensive Cancer Network (NCCN) considers polypectomy alone to be adequate therapy for low-grade invasive T1 polyps that are limited to the head/stalk region and can be excised with negative margins.
  • METHODS: The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database (1988-2003) was queried to identify patients with invasive T1 colonic polyps.
  • The percentage of node positivity was 7% after SR, or 8.9% if at least 12 nodes were resected.
  • The percentage of node positivity reached a surprising 6% in 1,478 patients who underwent SR for low-grade polyps limited to the head/stalk, and nodal status significantly affected the 3-year disease-specific survival of this subgroup: 83% with nodal metastases vs. 96% without nodal metastases (p < 0.003).
  • CONCLUSIONS: Malignant colonic polyps with favorable histological features have a 6% risk of lymph node metastases even when removed with negative margins, bringing into question the NCCN recommendation that PP alone is adequate therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ: Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol; 2009 May 20;27(15_suppl):5042
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
  • RESULTS: In multivariate analysis of sunitinib patients, factors associated with longer OS include: interval from diagnosis to treatment ≥1 yr, ECOG PS of 0, lower corrected calcium, absence of bone metastases, lower lactic dehydrogenase (LDH), and higher hemoglobin (Hgb) ( table ).
  • For the IFN-α treatment arm, male gender, absence of bone or lymph node metastases, lower LDH, higher Hgb, lower corrected calcium, higher neutrophil count, and interval from diagnosis to treatment ≥1 yr were associated with longer OS.
  • Further studies are warranted to independently validate these findings as well as to identify tumor-specific prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962940.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • : e15588 Background: This prospective study was performed to assess the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) with three drugs in patients with curative resection of T3 or T4 advanced gastric cancer.
  • METHODS: Patients with curative resection of clinically T3 or T4 advanced gastric cancer were required to be under 75 years of age and to have adequate organ function.
  • After the curative resection of gastric cancer with D2 lymph node dissection and the reconstruction of the alimentary tract, HIPEC was carried out for 30 minutes with 50mg of CDDP, 10mg of MMC, and 1000mg of 5-FU in 5 L saline maintained at 42-43°C.
  • Three patients with pT3 had recurrence of pleural dissemination (n=1), lymph node metastases (n=1), or pulmonary metastases and peritoneal dissemination (n=1).
  • CONCLUSIONS: The present study suggests that HIPEC with three drugs after curative resection of advanced gastric primary cancer is associated with improved overall survival with an acceptable morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Iwase H, Yamamoto Y, Kurebayashi J, Tsuda H, Ota T, Kurosumi M, Miyamoto K, Iwase T, Research Group of the Japanese Breast Cancer Society: Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e22122
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases.
  • To clarify the characteristics of TN tumors, the data of the registration committee of the Japanese Breast Cancer Society were analyzed with respect to clinicopathologic factors, response to neoadjuvant chemotherapy (NAC) and prognosis.
  • TN cancers were diagnosed at a slightly advanced stage and more of the cases had lymph node metastases compared to other types.
  • Pathological response rate of NAC, including grade 2 and 3, was higher in TN tumor as 51.5 % (22/53) than in Luminal A tumor as 16.7% (12/72).
  • Responders in TN tumors have a better prognosis than non-responder (P=.0016), but this tendency was not recognized in non-TN tumors (P=.15).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tada H, Tanaka M, Katakami N, Kurata T, Mitsudomi T, Negoro S, Kudoh S, Nishiyama H, Nishimura Y, Nakagawa K: Phase III study of induction chemotherapy (docetaxel and carboplatin) with or without radiotherapy followed by surgery in patients with stage IIIA (pN2) non-small cell lung cancer (NSCLC): WJTOG9903. J Clin Oncol; 2009 May 20;27(15_suppl):7556
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of induction chemotherapy (docetaxel and carboplatin) with or without radiotherapy followed by surgery in patients with stage IIIA (pN2) non-small cell lung cancer (NSCLC): WJTOG9903.
  • To gain insights on significance of preoperative chemoradiotherapy, we tried to evaluate feasibility and efficacy of induction chemotherapy with or without radiotherapy followed by surgery in patients with stage IIIA NSCLC with mediastinal lymph node metastases.
  • Patients subsequently underwent pulmonary resection if the tumor was judged resectable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963344.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Aoki Y, Inamine M, Hirakawa M, Kudaka W, Nagai Y: Heparanase expression and angiogenesis in endometrial cancer: Analyses of RT-PCR and immunohistochemistry. J Clin Oncol; 2009 May 20;27(15_suppl):5535
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase expression and angiogenesis in endometrial cancer: Analyses of RT-PCR and immunohistochemistry.
  • : 5535 Background: The human heparanase has been shown to function in tumor progression, metastatic spread, and tumor angiogenesis.
  • The aim of the present study was to assess heparanase expression in endometrial cancer in correlation with neovascularization and clinicopathological factors.
  • Tumor angiogenesis was assessed using microvessel counting.
  • RESULTS: The expression of heparanase mRNA was detected in 26 of 52 (50%) endometrial cancers, and was significantly correlated with FIGO stage IIIc (p = 0.0075), the presence of lymph-vascular space involvement (LVSI) (p = 0.0041), lymph node metastasis (LNM) (p = 0.0049), and histological tumor grade (p = 0.003).
  • IHC showed that the heparanase was expressed in 23 of 52 (44.2%) endometrial cancers, which was significantly related to LVSI (p = 0.0028), depth of myometrial invasion (p = 0.0026), and histological tumor grade (p = 0.0135).
  • Microvessel density was also associated with FIGO stage IIIc (p = 0.027), LVSI (p = 0.001), LNM (p = 0.038), ovarian metastasis (p = 0.03) and histological tumor grade (p = 0.003).
  • CONCLUSIONS: These results suggest that the expression of heparanase can promote tumor angiogenesis and develop metastasis in endometrial cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962489.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Osarogiagbon RU, Allen JW, Farooq A, Ninan M, Ratliff TW: Outcome of surgical resection for pathologic Nx and N0 non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7513
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of surgical resection for pathologic Nx and N0 non-small cell lung cancer (NSCLC).
  • : 7513 Background: Metastasis to lymph nodes (LN) connotes poor prognosis in NSCLC.
  • Patients with no LN examined (pNx) may be incompletely staged and erroneously assigned to a low risk group.
  • To evaluate this possibility, we compared the survival of patients with node negative disease and at least 1 LN examined (pN0) to those with pNx.
  • Benign and metastatic disease, pre-operative chemo/radio therapy, bronchoalveolar cell, small cell lung, carcinoid tumors and repeat lung resection were excluded.
  • RESULTS: 746 of 809 resections met inclusion criteria.
  • Most (85%) patients with pN0 had <10 nodes examined and a large proportion (35.1%) had no mediastinal LNs, raising the possibility of understaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963484.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Blackshaw G, Davies L, Escofet X, Crosby T, Roberts A, Clark G, Havard T, Lewis W: Influence of age on outcome after radical treatment of esophageal cancer with surgery or chemoradiotherapy (dCRT). J Clin Oncol; 2009 May 20;27(15_suppl):4569
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of age on outcome after radical treatment of esophageal cancer with surgery or chemoradiotherapy (dCRT).
  • METHODS: Prospective study of 504 consecutive patients managed by a single regional upper GI cancer network with curative intent based on CT, EUS and performance status; 270 underwent surgical based therapy [104 neoadjuvant chemotherapy, 49 neoadjuvant chemoradiotherapy, median age 61 (31-79) yr], and 234 dCRT [68 (41-83) yr].
  • On multivariable analysis, EUS T stage (HR 1.33, 95% CI 1.021 to 1.747, p=0.035), EUS defined lymph node metastasis count (HR 1.169, 95% CI 1.044 to 1.308, p=0.007), and age (HR 1.556, 95% 1.095 to 2.211, p=0.014) were independently and significantly associated with survival.
  • Elderly patients diagnosed with esophageal cancer are arguably better treated with dCRT than multimodal surgical therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Han W, Kim H, Lee J, Lee K, Moon H, Ko E, Kim E, Yu J, Noh D: Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):1105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis.
  • : 1105 Background: Preoperative clinical staging in breast cancer patients is important to determine the most appropriate treatment plans and to predict prognosis for individual patients.
  • Identifying unexpected distant metastases in newly diagnosed breast cancer patients frequently alters initial treatment plans.
  • Routine imaging studies to detect lung or liver metastasis is not indicated in patients with early and operable breast cancer.
  • A recent study showed that routine use of chest radiograph and liver ultrasound does not provide much diagnostic benefit in early breast cancer patients.
  • METHODS: We aimed to investigate the value of preoperative computed tomography to detect asymptomatic liver and lung metastasis in breast cancer patients.
  • We performed preoperative CT for 667 breast cancer patients to detect lung and liver metastasis among 1,636 primary breast cancer patients who had been diagnosed and treated between January 2006 and December 2007 at Seoul National University Hospital.
  • RESULTS: CT showed abnormal findings (suspicious of metastasis or indeterminate nodules) in 78 patients (10.5%).
  • Among these, abnormal finding in 13 patients (1.7%) turned out to be true metastatic lesions.
  • There was no CT-detected lung or liver metastasis in patients with T1 tumor and 4 metastases in patients with T2 tumor.
  • There was no CT-detected lung or liver metastasis in patients with negative axillary lymph node metastasis.
  • When patients were classified according to the AJCC staging, CT-detected true metastatic lesions were only present in stage III patients (13 out of 173 patients, 7.5%).
  • The true metastatic lesions in lung or liver were all small sized nodules, ranging from 0.3cm to 1.2cm in largest diameters.
  • In seven patients, the CT-detected metastatic lesions were less than 1cm which is in contrast with the previous studies.
  • CONCLUSIONS: Our results demonstrated the lack of usefulness in performing routine CT exams to detect asymptomatic liver and lung metastasis in early breast cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962171.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Caudle AS, Gonzalez-Angulo AM, Kelly HK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F: Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
  • : 603 Background: While most patients with breast cancer receiving neoadjuvant chemotherapy (NCT) have some tumor response, a small proportion progress during therapy.
  • The goal of this study was to identify predictors of tumor progression during NCT with the ultimate aim of identifying the subset of patients who may benefit from a first-line surgical approach.
  • METHODS: Patients with stage I-III breast cancer treated at a single comprehensive cancer center with NCT between 1994 and 2007 were included.
  • Data was obtained from a review of medical records of patients in a prospectively acquired database.
  • Predictive histopathological features were high tumor grade (p = 0.005), high Ki-67 (p = 0.002), and negative ER and PR status (p < 0.0001 and p = 0.0006).
  • In the post-NCT surgical specimens, patients with PD were more likely to have higher T stage (p < 0.0001), lymph node metastasis (p = 0.01), and lymphovascular invasion (p = 0.02).
  • CONCLUSIONS: Pre-treatment characteristics predictive of disease progression on NCT include advanced tumors, high tumor grade, high Ki-67, and negative ER or PR status.
  • Since high grade and negative ER/PR status have also been associated with a complete pathologic response to NCT, there is a clear need for more specific molecular predictors of response and progression in order to select appropriate treatment in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961464.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kurosumi M, Kobayashi Y, Takei H: The utility of a real-time RT-PCR assay for the detection of metastases greater than 0.2 mm in sentinel lymph nodes of breast cancer patients confirmed by detailed histological analysis. J Clin Oncol; 2009 May 20;27(15_suppl):628
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of a real-time RT-PCR assay for the detection of metastases greater than 0.2 mm in sentinel lymph nodes of breast cancer patients confirmed by detailed histological analysis.
  • : 628 Background: Analysis using real time RT-PCR for the detection of metastases in lymph nodes (LN) increases sampling but is associated with a risk of too much sensitivity as compared to histological analysis.
  • Our study confirms the reliability of the cutoff values of a real-time RT-PCR assay (GeneSearch, Veridex LLC) to detect metastases larger than 0.2 mm by detailed 0.2 mm frozen section histological diagnosis.
  • METHODS: 129 sentinel and non-sentinel lymph nodes were obtained by sentinel LN biopsy from 79 breast cancer patients.
  • One half of each LN was used for routine intra-operative diagnosis.
  • All frozen sections were H&E stained and examined by on-site pathologists.
  • Cutoff values were pre-set in a large US study (n = 304).
  • RESULTS: Compared to the histological diagnosis using 0.2 mm interval frozen sections, the real-time RT-PCR results were as follows; sensitivity of 100.0% (34/34), specificity of 93.7% (89/95), and overall accuracy of 95.3% (123/129).
  • CONCLUSIONS: Results of 0.2 mm interval histological analysis suggest a near perfect sensitivity of the real time RT-PCR assay, allowing reliable detection of LN metastases larger than 0.2 mm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961430.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hasegawa J, Yoshida Y, Mizushima T, Fujii M, Mizuno H, Tamagawa K, Nezu R: Outcome of initially unresectable advanced and metastatic colorectal cancer patients treated with first-line mFOLFOX6 followed by surgical tumor removal of metastases: Preliminary results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15122
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of initially unresectable advanced and metastatic colorectal cancer patients treated with first-line mFOLFOX6 followed by surgical tumor removal of metastases: Preliminary results of a phase II trial.
  • : e15122 Objective: The aim of this study was to evaluate the efficacy and tolerability of treatment with mFOLFOX6 followed by surgical tumor removal in patients (pts) with initially unresectable liver metastases and/or extrahepatic disease from colorectal cancer (CRC).
  • Eligibility criteria defined pts with advanced and metastatic CRC deemed not optimally resectable. mFOLFOX6 (oxaliplatin 85 mg/m<sup>2</sup>, l-leucovorin 200 mg/m<sup>2</sup>, and fluorouracil [400 mg/m<sup>2</sup> bolus followed by 2,400mg /m<sup>2</sup> as a continuous 46-hour infusion]) was administered every 2 weeks for a maximum of 10 cycles.
  • Main unresectable lesions were liver metastases in 10 pts and extrahepatic disease in 16 pts.
  • In 16 of these 24 pts who achieved the disease control, surgical tumor removal was performed (resectability 61%).
  • The main reasons for initial unresectability in these 16 pts were the presence of liver metastases (6 pts), para-aortic lymph-node metastases (4 pts), carcinomatous peritonitis (4 pts), direct invasion to neighboring organ (2 pts).
  • At a median follow-up of 13 months (range 5 -21), 5 pts had relapsed after surgical tumor removal.
  • CONCLUSIONS: Our data suggest that mFOLFOX6 has a significant antitumor activity in pts with not only liver metastases but also extrahepatic disease from CRC, allowing for successful resection of disease in a portion of pts initially not judged to be optimally resectable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hayashi M, Okumura Y, Ohsako T, Arima N, Nishimura R: Effect of trastuzumab on the reduction of hormone receptor expression by neoaduvant chemotherapy in HER2-positive breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11114
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of trastuzumab on the reduction of hormone receptor expression by neoaduvant chemotherapy in HER2-positive breast cancer.
  • : 11114 Background: Neoadjuvant chemotherapy (NAC) in primary breast cancer is actively used around the world.
  • Moreover, trastuzumab (T) has an established role in the management of HER-2 positive breast cancer in conjunction with chemotherapy.
  • METHODS: Since April 2002, 143 patients with tumors ≥3 cm in diameter or lymph node metastases have received NAC and surgery.
  • The treatment regimen were as follows; ET in 60 cases, FEC-DOC in 68 cases, and T with anthracycline and taxane in 15 cases.
  • RESULTS: The clinical response rate (CR+PR) was 84% in all patients.
  • The pathological CR (pCR) rate was 7.7% in the ET, 20.9% in the FEC-DOC and 33.3% in the T regimen.
  • Thus, ER and HER-2 expression may modify tumor biology via cross-talk even in NAC cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963496.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kaya AO, Gunel N, Benekli M, Akyurek N, Buyukberber S, Tatli H, Coskun U, Yildiz R, Yaman E, Ozturk B: Association of hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression and survival in HER2/neu positive hormone-unresponsive breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22078
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression and survival in HER2/neu positive hormone-unresponsive breast cancer patients.
  • In our study, we evaluated HIF-1alpha and CA IX expression in Her-2/neu positive hormone- unresponsive breast cancer patients.
  • METHODS: One hundred and eleven patients with operable breast cancer were identified who had paraffin-embedded tissue blocks available.
  • We assigned two groups with 56 patients who have ER and PR receptor positive, Her-2/neu negative (group 1) and with 55 patients who have ER and PR negative, Her-2/neu positive (group 2).
  • Additionally, we investigated the association between HIF 1 alpha and CA IX expressions with stage, grade, lymph node metastasis, tumor dimension and menopause status.
  • CONCLUSIONS: HIF-1 alpha and CA IX overexpressions were more frequently observed in ER and PR negative, Her-2/neu positive breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Bogoevski D, Schurr PG, Koenig AM, Busch P, Kutup A, Izbicki JR: Is there still place for endoscopic mucosal resection in patients with early oesophageal carcinomas? J Clin Oncol; 2009 May 20;27(15_suppl):e15640
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 111 patients with early oesophageal cancer (57 adenocarcinomas, 54 squamous cell carcinomas) had surgical resection with systematic lymphadenectomy (41 thoracoabdominal-TA, 52 transhiatal-TH and 18 with limited resection of the oesophagogastric junction- LROGJ).
  • The median lymph node yield was significantly higher (p=0.0001) in TA patients (24 LN), compared with TH (14LN) and LROGJ (16LN).
  • None of the 43 patients with high grade intraepithelial neoplasia (HGIEN) or oesophageal carcinoma limited to the mucosa had lymphatic spread, as compared with 15 of 68 (22.1%) with affection of the submucosa.
  • Although lymph node metastases were usually limited to locoregional lymph node stations, two patients had metastases in distant lymph nodes (pM1a) The infiltration of the submucosa was accompanied with significant worsening of the overall survival (pT1a vs. pT1b; p=0.002).
  • Multifocal neoplasia was detected in three patients with SCC HGIEN (30%) but not in AC HGIEN!
  • Nine out of 44 (20.4%) patients with early SCC had multifocal neoplasia, compared to 6 out of 53 (11.3%) patients in AC (p=0.322).
  • On multivariate analysis, only histological tumor type (AC) was independent predictor of survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962740.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Bromley E, Owczarczak B, Keltner L, Wang S, Gollnick SO: Characterization of an antitumor immune response after light-activated drug therapy using talaporfin sodium in a spontaneously metastasizing mammary tumor model. J Clin Oncol; 2009 May 20;27(15_suppl):3052
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of an antitumor immune response after light-activated drug therapy using talaporfin sodium in a spontaneously metastasizing mammary tumor model.
  • Tumor destruction involves direct and indirect tumor kill through apoptosis, vascular occlusion, and potentially antitumor immunologic effects.
  • To provide evidence for the potential antitumor immunologic effects, we have used the therapy to treat primary tumors and examine prevention of metastases in the 4T1 tumor model, an aggressive, spontaneously metastasizing murine mammary tumor model that mirrors human breast cancer.
  • When grown in the mammary fat pad of BALB/c mice, untreated 4T1 tumors rapidly metastasize to lung, liver, lymph nodes, and brain.
  • METHODS: To confirm tumor kill by this therapy, the primary 4T1 tumors grown in mice were treated and animal survival was followed.
  • To determine whether the therapy could enhance antitumor immunity and reduce metastases, the lymph node (LN) cells from treated and control mice were transferred to naïve recipient mice.
  • Recipients were challenged with a tumorigenic dose of 4T1 cells 3 days after adoptive transfer and primary and secondary tumor growth in the recipients was examined.
  • LN cells isolated from treated mice, but not control mice, significantly inhibited primary tumor growth in recipients (p≤0.0001) and dramatically reduced the number of lung metastases present 40d after tumor challenge (p≤0.02).
  • The ability to inhibit primary and secondary tumor growth in recipients depended on the presence of CD8<sup>+</sup> T cells; depletion of CD8<sup>+</sup> T cells from the LN abolished the effect.
  • CONCLUSIONS: These results indicated that this light-activated drug therapy not only destroyed the treated tumors directly but also controlled growth of untreated tumors through induction of a specific host antitumor immune response mediated by CD8<sup>+</sup> T cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Karakunnel JJ, Gulley JL, Arlen P, Mulquin M, Wright J, Turkbey IB, Choyke P, Figg WD, Dahut W: Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5141
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC).
  • : 5141 Background: There is no standard therapy for prostate cancer patients who have progressed following docetaxel therapy.
  • VEGF is implicated in tumor blood vessel formation and in disease progression in several solid tumors.
  • RESULTS: Thirty-four of a planned 35 patients have been enrolled and 4 remain on active treatment (2-7 months).
  • There have been 13 of 23 evaluable patients with tumor shrinkage and 4 have met the criteria for partial response.
  • Decreases in lymph node metastases as well as in lung, liver and bone lesions have occurred.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Endo M, Watanabe H, Yamamoto S, Yamamoto N, Ohe Y, Tamura T: Impact of revised lymph node measurement rules in the new RECIST version 1.1 on the tumor response evaluation in patients with advanced lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7567
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of revised lymph node measurement rules in the new RECIST version 1.1 on the tumor response evaluation in patients with advanced lung cancer.
  • 1.1 was published in a special edition of the European Journal of Cancer in the first quarter of 2009 (EJC 2009;45:228).
  • The major change involves the rules for lymph node measurement, which is to measure SHORT axis in stead of the longest diameter of lymph node.
  • To be considered pathologically enlarged and measurable, a size of lymph node must be at least 15mm in short axis when assessed by CT scan.
  • Lymph nodes that are at least 10mm but less than 15mm in short axis may be pathologic and can be considered as non-measurable/non-target lesions (not measured).
  • 1.0 in patients with advanced lung cancer.
  • METHODS: Two radiologists independently reviewed the objective tumour response of 305 patients (pts) with advanced lung cancer who had primary lesion and lymph node metastases as target lesions measured more than 10 mm in the longest diameter.
  • The tumor responses were divided into four categories (CR, PR, SD, PD), following proportion of agreement and estimation of kappa statistics between two the criteria as agreement measure.
  • Out of the 108 pts with PR by ver.1.0, 8.3 % were downgraded to SD and 1.0 % was categorized as PD by ver.1.1.
  • On the other hand, out of the 190 pts with SD by ver.1.0, 6.3 % were upgraded to PR and 8.9 % were downgraded to PD by ver.1.1.
  • CONCLUSIONS: No significant impact was observed for the revised lymph node measurement rules in the new RECIST ver.
  • 1.1 on the response evaluation in pts with advanced lung cancer registered in this analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963363.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Wilgenhof S, Van Nuffel AM, Benteyn D, Pierret L, Heirman C, De Coninck A, Van Riet I, Bonehill A, Thielemans K, Neyns B: Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9024
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9024 Background: Electroporation of dendritic cells (DC) with mRNA encoding fusion-proteins of a HLA-class II targeting signal and a melanoma associated antigen (MAA) together with mRNA encoding CD40 ligand, a constitutively active TLR4 and CD70 (TriMix) improves the immunostimulatory capacity of autologous DC.
  • Immune monitoring is performed by skin biopsy of a vaccine injection site.
  • RESULTS: 29 pts (17M/12F; med age 49, range 28-75) with stage III/IV melanoma, nl LDH, and no CNS metastases were recruited.
  • Vaccine related AE's (first 24 pts): gr2 local injection site reactions (all pts); fever & lethargy (gr2, 1 pt).
  • Out of the 13 pts with measurable disease, BOR (RECIST) was 8 SD and 5 PD; 1 pt with initial PD subsequently obtained a PR.
  • Regression of metastases occurred in lung- (2 pts), orbita- (1 pt) and lymph node metastases (3 pts).
  • CONCLUSIONS: Therapeutic vaccination with TriMix-DC combined with sequential IFN-a2b is feasible, safe, immunogenic and associated with anti-tumor activity in patients with advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962374.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Morrow PH, Divers SG, Provencher L, Luoh S, Petrella TM, Giurescu M, Fielding L, Wang Y, Hortobagyi GN, Vahdat LT: Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1083
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC).
  • It has shown significant pre-clinical activity in taxane resistant breast cancer cell lines and in tumor models, as well as clinical activity in both taxane naïve and pretreated MBC.
  • The primary end point was tumor response by RECIST.
  • Majority of metastases were in lymph nodes (62%), liver (55%), bone (49%), lung (37%), and cutaneous sites (19%).
  • Neither arm met Stage 1 criteria for responders.
  • Nevertheless, 2 patients in arm A and 1 in arm B had confirmed partial response, and lasted 4, 7, and 2 months, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961231.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Santana-Davila R, Visscher DW, Vachon CM, Frost M, Vierkant RA, Anderson SS, Degnim AC, Hartmann LC: Clinicopathological characteristics of subsequent breast cancers in patients with benign breast disease. J Clin Oncol; 2009 May 20;27(15_suppl):1061
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 1061 Background: Benign breast disease (BBD) is a significant risk factor for breast cancer (BC); however little is known about the aggressiveness of the BCs these patients develop.
  • With a median of 18 years of follow-up, 799 patients with BBD have developed breast cancer, 416 initially had NP, 313 had PDWA, and 70 AH.
  • In 537 cases the malignant tissue had a concurrent benign component consisting of NP in 24% (n = 129), PDWA in 25.1% (n = 135), and AH in 50.8% (n = 273).
  • In regards to tumor size, 69.6% had T1 tumors, 24.9% T2 tumors, and 5.5% T3 disease.
  • Metastasis to lymph nodes occurred in 25% of patients.
  • Breast cancer developed within 5 years from the initial BBD in 163 women (20%).
  • In this group, tumor size was greater (p = 0.02), and there were more poorly differentiated tumors (p = 0.006) than in those who later developed BC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Peacock N, Saleh M, Bendell J, Rose AA, Dong Z, Siegel PM, Crowley E, Simantov R, Vahdat L: A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1067
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC).
  • : 1067 Background: Glycoprotein NMB (GPNMB), also known as osteoactivin, has been shown to regulate metastasis of breast cancer in vivo.
  • This is the first study of CR011-vcMMAE in breast cancer.
  • Immunohistochemistry (IHC) with goat polyclonal antibody to GPNMB was performed on pt biopsy specimens and on tissue microarrays containing normal breast, DCIS, breast tumor and lymph node metastases.
  • A response of 37% tumor shrinkage was seen in a pt after only 2 cycles and is ongoing.
  • Breast tumor samples were more likely to stain positive for GPNMB than normal breast tissues.
  • IHC of pt tumor specimens is being evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961164.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Goda H, Nakashiro K, Yoshimura T, Sumida T, Wakisaka H, Hato N, Hyodo M, Hamakawa H: One-step nucleic acid amplification for detecting lymph node metastasis of head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6028
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-step nucleic acid amplification for detecting lymph node metastasis of head and neck cancer.
  • : 6028 Background: Lymph node stage is an important prognostic factor in squamous cell carcinoma of the head and neck (SCCHN).
  • We previously reported the clinical usefulness of sentinel lymph node (SLN) biopsy diagnosed by concurrently performing histological examination using semiserial sections and genetic analysis by quantitative RT-PCR.
  • In this study, we have attempted to develop a more efficient method for intraoperative genetic detection of lymph node metastasis in SCCHN.
  • METHODS: A total of 291 lymph nodes (59 patients) resected on SLN biopsy for cN0 SCCHN or neck dissection for cN1/2 SCCHN were diagnosed by one-step nucleic acid amplification (OSNA) method using GD-100.
  • The primary site was tongue, gingiva, oral floor, buccal mucosa, and pharynx in 44% (26), 37% (22), 10% (6), 5% (3), and 3% (2), respectively.
  • OSNA consists of a short homogenization step followed by amplification of cytokeratin 19 (CK19) mRNA directly from the lysate.
  • Amplification and detection of CK19 mRNA can be completed in a single step.
  • Each lymph node was divided into two halves to diagnose metastasis.
  • An alternative half was used for the OSNA assay with cytokeratin 19 (CK19) mRNA, and the remaining block was subjected to semiserial sectioning, sliced at 200-μm intervals and then examined by H&E and cytokeratin AE1/AE3 immunohistochemical staining.
  • RESULTS: Fifty-four of 291 lymph nodes were pathologically metastasis-positive.
  • The optimal cut-off for the copy number of CK19 mRNA in assessing lymph node metastasis was 300 copies/μl, which had the highest diagnostic accuracy.
  • CONCLUSIONS: The OSNA assay showing high sensitivity and specificity can be used as a novel genetic detection tool of lymph node metastasis in SCCHN patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Murakami F, Ogawa N, Yamazaki A, Sakurai S, Ishiya T, Katase K, Shimizu Y, Tanada S: Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5593
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma.
  • : 5593 Background: To evaluate the sensitivety, specificity, and accuracy of PET-CT for detecting lymph node metastasis in gynecologic carcinoma.
  • For pathological metastatic lymph nodes, the size of intranodal tumor deposits (maximum diameter of metastatic foci in each lymph node) were recorded.
  • RESULTS: The total number of pelvic lymph nodes (PLNs) plus paraaortic lymph nodes (PANs) removed was 2426.
  • The median number of removed lymph nodes (LNs) was 67 each pts (range: 25 to 102).
  • The sensitivity, specificity and accuracy of preoperative PET-CT to detect LN metastasis were 24%, 99.9%, and 97.5%, respectively.
  • FDG-PET detected 100% of intranodal tumor deposits > or =10 mm, whereas tumor deposits smaller than 5 mm were not detected.
  • CONCLUSIONS: The results of our study revealed 76% underdiagnosis (overlooking) in evaluation of preoperative PET-CT in LN metastasis.
  • Particularly, tumor deposits smaller than 5 mm were not detected at all.
  • Using PET-CT for detecting small LN metastasis in gynecologic carcinoma may be unreliable so far.
  • The improved usability and application of PET-CT for detecting LN metastasis in gynecologic carcinoma have to keep researching constructively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Tracy RA, Chuang ST, Kim J, Coppola D: Correlation of expression of pro-apoptotic proteins bax and bak with lymph node metastasis in colonic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15042
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of expression of pro-apoptotic proteins bax and bak with lymph node metastasis in colonic adenocarcinoma.
  • : e15042 Background: Colon cancer has been associated with disturbances in the regulation of apoptosis.
  • Down regulation of Bax and Bak, members of the Bcl-2 family, are associated with tumor metastasis.
  • Here we investigate how these two pro-apoptotic markers correlate with lymph node (LN) metastasis in colonic adenocarcinoma (CA).
  • These were than correlated with LN metastasis.
  • Within the ≤2 category, 23 of 67 (34%) tumors had no LN metastases while 15 of 21 (71%) in the ≥3 category had no metastasis (p= 0.0029).
  • Five of 23 (22%) tumors with a score ≤2 had no metastases and 35 of 77 (46%) with score ≥3 had no metastases (p= 0.0427).
  • The LOGISTIC Procedure was used to show that a patient with a ≥3 Bax score has a 4.78 times odds ratio (95% C.I.: 1.64- 13.98) of having no metastases while a patient with a ≥3 Bak score has a 3 times odds ratio (95% C.I.: 1.01- 8.90) of having no metastases.
  • CONCLUSIONS: We show correlation of the pro-apoptotic proteins Bax and Bak with decreased lymph node metastasis in CA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964458.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Bastiaannet E, De Jong JR, Brouwers AH, Suurmeijer AJ, Hoekstra HJ: The prognostic value of FDG-PET measured by standardized uptake value in patients with melanoma stage III evaluated in a prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):e20000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of FDG-PET measured by standardized uptake value in patients with melanoma stage III evaluated in a prospective study.
  • : e20000 Background: FDG-PET is a sensitive modality to detect melanoma metastases; melanomas are typically FDG-avid and melanoma shows an unpredictable pattern of spread.
  • Therefore, aim of this study was to perform a prospective analysis to determine whether SUV is of prognostic value in the DFS and DSS of melanoma patients with palpable lymph node metastases.
  • METHODS: From July 2002 until December 2007, all consecutive patients with palpable, histology or cytology proven lymph node metastases of melanoma referred to the University Medical Centre Groningen for examination with FDG-PET were prospectively included.
  • The SUVmean (70% isocontour) and SUVmax in the lymph node metastasis were calculated for patients who showed no distant metastases on chest X-Ray, FDG-PET and CT.
  • High SUV values were present in axillary metastases (p=0.118), in patients who had more than 15 nodes removed (p=0.061) and in patients with a large tumor size in the lymph node (p=0.0001).
  • CONCLUSIONS: The SUV in the lymph node metastasis seems to be associated with disease-free survival for melanoma patients clinically stage III.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962608.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Twine C, Rawlinson C, Escofet X, Blackshaw G, Crosby T, Roberts A, Lewis W: Prognostic significance of the endoluminal ultrasound defined lymph node metastasis count in esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4558
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the endoluminal ultrasound defined lymph node metastasis count in esophageal cancer.
  • : 4558 Background: TNM histopathological staging system for esophageal cancer is controversial, and will soon be revised to account for the relative burden of the number of lymph node metastases.
  • The aim of this study was to assess the prognostic significance of endoluminal ultrasound (EUS) defined lymph node metastasis count (eLNMC) in patients with esophageal cancer.
  • Median and 2 year survival for patients with 0, 1, 2 to 4, and >4 lymph node metastases were: 44 months and 71%; 36 months and 59%; 24 months and 50%; and 17 months and 32% respectively.
  • CONCLUSIONS: The eLNMC was an important and significant prognostic indicator in patients with esophageal cancer, which should in future be reported and used to revise the perceived radiological stage, in order to inform stage directed multimodal therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963027.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Raoul J, Craxi A, Porta C, Lentini G, Nadel A, Voliotis D, Bruix J, Llovet JM: Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15547
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial.
  • : e15547 Background: Results from the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, a multinational, randomized, placebo-controlled, phase III trial, demonstrated that sorafenib is effective and safe for patients with advanced HCC (Llovet et al, N Engl J Med, 2008).
  • As lymph nodes are among the most common sites of metastasis in patients with HCC, we performed subset analyses to evaluate the efficacy and safety of sorafenib in patients with or without lymph node metastases at baseline.
  • CONCLUSIONS: Sorafenib prolonged OS and TTP in patients with advanced HCC, whether or not lymph node metastases were present at baseline.
  • The safety profile of sorafenib in patients with lymph node metastases was comparable with that for the overall study population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Pomara G, Campo G, Milesi C, Casale P, Francesca F: How many lymph nodes may serve as a guideline for a sufficient extended lymph node dissection during radical prostatectomy? J Clin Oncol; 2009 May 20;27(15_suppl):e16102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How many lymph nodes may serve as a guideline for a sufficient extended lymph node dissection during radical prostatectomy?
  • : e16102 Background: Recent data suggest that extended lymph node (LN) dissection at radical prostatectomy (RP) may be necessary to detect occult positive lymph nodes, and that extended dissection may also have a positive impact on disease progression and long-term disease-free survival.
  • However, evaluation of lymphadenectomy to be complete and sufficient as judged by the number of removed lymph nodes is sometimes difficult.
  • Some authors reported that approximately 20 pelvic lymph nodes may serve as a guideline for a sufficient extended lymph node dissection during RP.
  • 2) to evaluate the effect of the number of LNs removed on lymph node metastasis.
  • The number of lymph nodes extracted and the number of patients with positive lymph nodes detected were analyzed and compared.
  • RESULTS: Analyzing all the population, the median number of removed lymph nodes was 15 (1-39).
  • Analyzing only the most experienced surgeon results, the median number of removed lymph nodes was 20 (range 6-39).
  • The effect of the number of LNs removed on lymph node metastasis is shown in the Table .
  • CONCLUSIONS: Compared to limited lymph node dissection (< 10 removed LNs), extended pelvic lymphadenectomy appears to identify men with positive lymph nodes more frequently.
  • Although very experienced surgeons remove approximately 20 pelvic lymph nodes (comparable to the literature), our results seem to underline that 15 removed LNs are sufficient as a guideline for an extended lymph node dissection during RP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963350.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Rino Y, Yukawa N, Murakami H, Masuda M, Oshima T, Sato T, Yamamoto N, Imada T: Usefulness and faults of the sentinel lymph node biopsy using dye technique in distal gastrectomy for gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15509
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness and faults of the sentinel lymph node biopsy using dye technique in distal gastrectomy for gastric cancer.
  • : e15509 Background: We apply sentinel node biopsy (SNB) in distal gastrectomy to perform it as safe limited surgery.
  • Limited surgery is a procedure in which the extent of lesion resection and lymph node dissection is reduced.
  • We assessed usefulness and faults of intraoperative diagnosis of lymph node metastasis in this regard.
  • METHODS: Surgical procedures: Patent blue (1%) is injected submucosally into 4 to 5 different sites at 1 mL per site around the primary tumor.
  • If blue nodes are found, biopsy and diagnosis of metastasis are performed at this point.
  • SUBJECTS AND METHODS: The study was conducted in 96 gastric cancer patients with a preoperative diagnosis of T1 or mp invasion.
  • Tumor invasion of m, sm, mp, ss, and se was identified in 44, 38, 8, 2, and 4 patients, respectively.
  • Of the 34 patients in whom BNs were identified, 5 had metastases in BNs confirmed by intraoperative frozen section diagnosis in DG cases.
  • On the other hand, of the 58 LADG patients in whom BNs were identified, 5 had metastases in BNs confirmed by intraoperative frozen section diagnosis in LADG case.
  • For the case that shows infiltration up to MP, the possibility of lymph node metastasis for other lymph node is considered to be negligible.
  • In consequence, as long as the infiltration is lower than MP, and confirmed that metastasis was not found by blue node biopsy, distal gastrectomy using limited surgery would be thought to be done safely.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962239.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Huang W, Weidler J, Lie Y, Whitcomb J, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen P, Bates M, Joensuu H: Correlation of quantitative total HER2 expression and HER2 homodimers with histopathologic characteristics of breast cancers in the FinHer study. J Clin Oncol; 2009 May 20;27(15_suppl):11061
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11061 Background: We recently reported that the HERmark assay (Monogram Biosciences) accurately measures continua of total HER2 expression (H2T) and HER2 homodimers (H2D) over a wide (∼3 logs) dynamic range, and that a higher concordance was observed between H2T and HER2 status with more stringent central tests as compared with IHC tests performed locally (Joensuu et al, 2008 SABCS,abstract 2071).
  • H2D/H2T ratio was reported as a marker of activated HER2 and a prognosticator of disease progression in HER2+ patients not treated with trastuzumab in the adjuvant setting (Bates et al, 2008 SABCS,abstract 1074).
  • The results were correlated with histopathologic characteristics of breast cancers in the FinHer study (Joensuu et al, N Engl J Med2006;354), including estrogen receptor/progesterone receptor (ER/PR), tumor grade, tumor size, lymph node metastasis, and stage.
  • RESULTS: Higher H2T and H2D levels correlated with ER/PR negativity and high tumor grade (P<0.0001).
  • 42% (102/244) of ER- and 37% (137/374) of PR- cases were HERmark Positive; while 17% (110/655) of ER+ and 14% (75/524) of PR+ cases were HERmark Positive.
  • No significant association was found between H2T or H2D and tumor size, lymph node metastasis or stage.
  • ER/PR negative and poorly differentiated cancers had higher H2D/H2T ratios (P=0.013), and H2D/H2T ratios >0.6 were associated with smaller primary tumor diameters at the time of cancer detection (P=0.009).
  • CONCLUSIONS: The quantitative H2T measurement confirms the known correlations between HER2 expression and histopathologic characteristics of breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963133.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Di Filippo F, Mottolese M, Botti C, Marandino F, Psaila A, Perri P, Di Filippo S, Pasqualoni R, Ferranti F, Buglioni S: A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by one step nucleic acid amplification (OSNA) in comparison to intensive histological investigation. J Clin Oncol; 2009 May 20;27(15_suppl):609
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by one step nucleic acid amplification (OSNA) in comparison to intensive histological investigation.
  • : 609 Background: The aims of the study were 1) to assess the accuracy of a new intra-operative molecular diagnostic tool named OSNA, based on the measurement of cytokeratin 19 (CK19) mRNA, in the detection of axillary sentinel lymph node (SLN) metastases in patients with breast carcinoma 2) to determine the concordance of OSNA analysis with multilevel haematoxylin and eosin (H&E) and immunohistochemical (IHC) examination.
  • METHODS: A prospective series of 247 consecutive SLNs from 187 breast cancer patients was evaluated.
  • The remaining two slices were investigated by six-level histopathology with 100 μm skip ribbons using routine H&E and CK19 IHC staining.
  • CONCLUSIONS: The current study suggests that the performance provided by OSNA assay is comparable to intensive histopathological work-up even when using only half a lymph node.
  • The method could be applied as a rapid and reliable intra-operative diagnostic tool thus preventing breast cancer patients from a diagnostic delay or second surgery due to a postoperatively diagnosed positive SLN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961472.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Choi J, Ahn M, Park Y, Oh Y, Park K, Jeong H, Son Y, Baek C, Ahn Y: EZH2 expression and correlation with Ki-67 and p53 in head and neck squamous cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e17018
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the role of EZH2 expression in head and neck cancer has not yet been fully determined.
  • This study was conducted to investigate the clinical value of EZH2 expression in head and neck cancer and its correlation with Ki-67 and p53 expression.
  • However, we found no significant differences in other clinicopathological parameters (age, sex, primary tumor size, and lymph node metastasis) and survival between the EZH2 positive and negative groups.
  • CONCLUSIONS: These results suggest that high EZH2 expression may be associated with tumor cell proliferation and cell cycle regulation in head and neck cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961709.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Song J, Choi S, Lee J, Lim S: Cytoplasmic expression of HuR and cyclooxygenase-2 expression in colon cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22161
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic expression of HuR and cyclooxygenase-2 expression in colon cancer.
  • METHODS: We investigated the expression and its cellular location of HuR, and Cox-2 expression in 79 colorectal cancer patients with immunohistochemistry, and evaluated the biological implications in colorectal carcinoma.
  • And cytoplasmic expression of HuR showed correlation with lymphatic invasion (p=0.025) and lymph node metastasis (p=0.027).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Al-Moundhri MS, Al-Nabhani M, Burney I, Rizvi A, Al-Farsi A, Al-Bahrani B: Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms in an Omani population. J Clin Oncol; 2009 May 20;27(15_suppl):4568
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms in an Omani population.
  • : 4568 Background: VEGF plays a central role in the angiogenesis, tumor growth and metastasis.
  • VEGF gene polymorphisms at various loci and gastric cancer (GC) risk predisposition and their prognostic significance were studied previously with controversial results Methods: We analyzed three VEGF polymorphisms (+405 G>C, -460T>C, and +936C>T) by extraction of genomic DNA from peripheral blood of 130 GC patients and 130 control subjects followed by VEGF genotyping using PCR-RFLP analysis and the determination of the polymorphisms GC risk predisposition and their prognostic significance Results: There was no significant association between the VEGF polymorphisms and gastric cancer risk.
  • There was a significant correlation between +405 C/C genotype and poor tumor differentiation (p=0.007) and lymph node metastasis (p=0.03) and 460T/T genotype and poor differentiation (p=0.03) with statistical trend for lymph node involvement (p=0.05).
  • Multivariate analysis showed that disease stage at diagnosis, and +405 G/G genotype were independent variables of adverse prognostic significance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963052.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Rohatgi A, Naji S, Hamouda A, Ross PJ, Mason RC: Effect of understaging of early oesophageal tumors on treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e15572
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15572 Background: Early and node negative oesophageal cancers do not undergo chemotherapy as it is felt that as the risk of lymph node metastasis is small, early operative intervention is considered the best option.
  • We analysed a prospective database in a tertiary referral centre to see, with current preoperative staging modalities, if a significant number of patients were under staged and hence under treated preoperatively.
  • METHODS: Four hundred and fifteen patients underwent esophagectomies for cancer in our unit between March 2000 and December 2006.
  • These were discussed in a multi-disciplinary meeting and as per current evidence did not undergo preoperative chemotherapy.
  • We feel that early oesophageal cancer especially T2N0 disease may benefit from neoadjuvant chemotherapy based on the current staging protocols.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Shrestha E: The expression and clinical significance of clusterin and ki67 in cervical cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16554
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and clinical significance of clusterin and ki67 in cervical cancer.
  • : e16554 Background: To explore the expression pattern and clinical significance of the CLU and proliferation indices ki67 in cervical cancer.
  • METHODS: 59 cases treated at Cancer Center Sun Yat-sen University during 1989-2006 were enrolled in the study group.
  • The expression of CLU and Ki67 had no correlation with FIGO stage, SCC antigen level, grade of differentiation, deep stromal invasion, and lymph node metastasis.
  • CONCLUSIONS: CLU and Ki67 was in lower rates in cervical cancer, and was not associated with any clinicopathological features.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960809.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Ke L, Wei H, Na L, Na L, Xin W, Qing-Xia F: Effect of N-cadherin knock-down on invasiveness of esophageal squamous cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of N-cadherin knock-down on invasiveness of esophageal squamous cell carcinoma.
  • : e15571 Background: Cell adhesion molecules are of crucial importance in cancer invasion and metastasis.
  • AIM: To examine the expressions of N-cadherin and E-cadherin in 62 normal esophageal epithelium specimens, 31 adjacent atypical hyperplasia epithelium specimens and 62 esophageal squamous cell carcinoma specimens, and to investigate the roles of N-cadherin in the invasiveness of esophageal squamous cell carcinoma cell line EC9706 transfected by N-cadherin shRNA..
  • METHODS: PV immunohistochemistry was used to detect the expression pattern of N-cadherin and E-cadherin in 62 normal esophageal epithelium specimens, 31 adjacent atypical hyperplasia epithelium specimens and 62 esophageal squamous cell carcinoma specimens.
  • RESULTS: The positive rates of N-cadherin decreased in the sequence of carcinoma, adjacent atypical hyperplasia and normal esophageal tissue, which were 75.8%, 61.3%, 29.0% (P < 0.05), respectively, while those of E-cadherin increased in sequence, which were 40.3%, 71.0% and 95.2% (P < 0.05).
  • The increased expression of N-cadherin and decreased expression of E-cadherin were related to the invasion, differentiation, and lymph node metastasis (P < 0.05).
  • The expression level of N-cadherin decreased in the N- cadherin knocked down cells, and the invasiveness of those cells decreased significantly as well in vitro and in vivo.
  • CONCLUSIONS: These results suggest that N-cadherin is an important factor in the invasiveness of esophageal squamous cell carcinoma and N-cadherin may serves as a potential molecular target for biotherapy of esophageal squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Dangal G: Surgical treatment for early cervical cancer: Experience at a cancer hospital in Nepal. J Clin Oncol; 2009 May 20;27(15_suppl):e16575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for early cervical cancer: Experience at a cancer hospital in Nepal.
  • This study concentrates on the evaluation of our early experience in radical hysterectomy for cervical cancer in Nepal.
  • METHODS: This was a retrospective analysis of 48 patients who had radical hysterectomy with bilateral pelvic lymphadenectomy for early cervical cancer at the BP Koirala Memorial Cancer Hospital (BPKMCH) from September 2002 through September 2005.
  • Pelvic lymph node metastasis was found in 10 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Bandyopadhyay S, Nahleh Z, Ali Fehmi R, Arabi H, Sakr W, Munkarah A, Kruger M: Enhancer of zeste homologue 2 ( EZH-2) expression in breast cancer: a novel marker and potential target. J Clin Oncol; 2009 May 20;27(15_suppl):e22154
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancer of zeste homologue 2 ( EZH-2) expression in breast cancer: a novel marker and potential target.
  • : e22154 Background: EZH-2 is a protein involved in cell cycle regulation; it belongs to the Polycomb group of proteins and has been suggested to be associated with aggressive breast cancer.
  • In our study we investigate the expression of EZH2 in a cohort of hormone receptor negative breast carcinomas.
  • Tumor grade, size, presence or absence of DCIS, lymph node status and Her2/neu expression were documented.
  • Using the Mann-Whitney U test, the expression of EZH2 was correlated with the tumor characteristics listed above.
  • Increasing expression of EZH2 was correlated with increase in tumor size (>2 cm) and increased incidence of lymph node metastasis.
  • No correlation was seen with tumor grade, the presence or absence of DCIS and Her2/neu expression.
  • CONCLUSIONS: Our findings suggest that EZH2 is expressed in the majority of HR - breast cancer and is associated with aggressive breast carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Kiyohara H, Kato S, Ohno T, Ohkubo Y, Tamaki T, Kamada T: Carbon ion radiotherapy for malignant melanoma of female genital organs. J Clin Oncol; 2009 May 20;27(15_suppl):e16548
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiotherapy for malignant melanoma of female genital organs.
  • : e16548 Background: Malignant melanoma of the female genital organs is a very rare tumor and resistant to conventional photon radiotherapy.
  • We report six cases of female genital malignant melanoma those were well controlled locally by carbon ion radiotherapy (CIRT).
  • METHODS: Between November 2004 and October 2008, six patients with unresectable female genital malignant melanoma were treated with CIRT.
  • The tumor located in the vagina (4 patients), both the cervix and the vagina (1 patient), or both the vagina and the vulva (1 patient).
  • Two patients had inguinal lymph node metastasis and two had distant metastases at CIRT.
  • No late toxicity of greater Grade 2 was experienced, while Grade 1 proctitis was observed in a patient.
  • The four patients without distant metastasis were alive with no evidence of disease for 9-20 months after CIRT.
  • The two patients with distant metastases died from metastatic disease 13 and 18 months after CIRT, respectively.
  • CONCLUSIONS: CIRT achieved favorable local tumor control without developing severe acute and late toxicity in the treatment of unresectable malignant melanoma of the female genital organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960818.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Kakeji Y, Mizokami K, Sumiyoshi Y, Yoshinaga K, Saeki H, Tokunaga E, Endo K, Morita M, Kitao H, Emi Y, Maehara Y: The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4571 Background: Hypoxia caused by either radiation or chemotherapy induces various intracellular adaptive responses, which contribute to tumor progression.
  • The clinicopathological characteristics of human gastric cancer and the clinical outcomes were analyzed to investigate the effects of the expression of hypoxia-inducible factor1α (HIF-1α) and some related proteins, such as, vascular endothelial growth factor (VEGF), insulin-like growth factor-2 (IGF-2), p21, and p53 on the prognosis of human gastric cancer.
  • METHODS: The expressions of HIF-1α, VEGF, IGF-2, p21, and p53 proteins were determined by immunohistochemistry in 216 specimens of primary gastric cancer.
  • In addition, the HIF-1α expression positively correlated with the tumor size and depth of invasion, while it was also more frequent in tumors with lymphatic invasion and undifferentiated adenocarcinomas.
  • A multivariate Cox regression analysis showed the depth of invasion, lymph node metastasis, and HIF-1α positivity to all be independent prognostic factors in patients with gastric cancer.
  • CONCLUSIONS: Based on the above findings, HIF-1α is therefore considered to be a useful independent prognostic factor in gastric cancer, and the combination of a HIF-1α protein overexpression with the loss of p21 expression or nonfunctional p53 thus tends to indicate a dismal prognosis.
  • Controlling hypoxia, especially in the HIF-1α pathways, may therefore hold the key to a greater individualization of therapy and also lead to the development of new treatments for patients with gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Kitagawa Y, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Sakamoto J, Aikou T, Kitajima M: Prospective multicenter trial of sentinel node mapping for gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4518
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter trial of sentinel node mapping for gastric cancer.
  • : 4518 Background: The sentinel node (SN) concept has revolutionized the approach to the surgical staging of both melanoma and breast cancer, and these techniques can yield patient benefit by avoiding various complications due to unnecessary prophylactic regional lymph node dissection in cases with negative SN for cancer metastasis.
  • Clinical application of SN mapping for early gastric cancer had been controversial for years.
  • However, single institutional results of SN mapping for early gastric cancer are almost acceptable results in terms of detection rate and accuracy to determine lymph node status.
  • We hypothesized that SN mapping plays a key role to obtain individual information and allows modification of the surgical procedure for early gastric cancer.
  • METHODS: The Japan Society of Sentinel Node Navigation Surgery (JSNNS) has conducted a prospective multicenter trial of SN mapping by a dual tracer method with radioactive colloid and blue dye.
  • Between September 2004 and March 2008, 433 patients with early gastric cancer were accrued at 12 comprehensive hospitals.
  • Eligibility criteria were that patients had clinically T1N0M0 or T2N0M0 single tumor with diameter of primary lesion less than 4cm without any previous treatments.
  • RESULTS: SN mapping has been performed for 397 patients with early gastric cancer.
  • Detection rate of hot and/or blue node using our procedure was 97.5% (387/397).
  • The mean number of sentinel nodes per case was 5.6.
  • Fifty-three of 57 cases with lymph node metastasis showed positive sentinel nodes.
  • The sensitivity to detect metastasis based on SN status was therefore 93% in our experience.
  • Accuracy of metastatic status based on SN was 99% (383/387).
  • In two of the four SN false-negative cases, the tumor involved to pT2, and only one case showed the metastatic lymph node beyond the SN basin.
  • CONCLUSIONS: Our results suggest that SN concept for clinically N0 early gastric cancer could be validated, and minimized gastrectomy with individualized selective and modified lymphadenectomy for early gastric cancer with negative SN should become feasible and clinically useful as less invasive surgical procedures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Mouawad R, Comperat E, Spano JP, Izzedine H, Cajfinger F, Deray G, Capron F, Khayat D: Expression and circulating levels of lymphangiogenic parameters in renal cell cancer: Implication for antiangiogenic treatments. J Clin Oncol; 2009 May 20;27(15_suppl):e16144
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and circulating levels of lymphangiogenic parameters in renal cell cancer: Implication for antiangiogenic treatments.
  • : e16144 Background: Vascular endothelial growth factors C, VEGF-D and VEGFR-2, R-3, are overexpressed in different malignancies and associated with lymph node metastasis and poor prognosis.
  • In renal cell cancer (RCC) lymphatic tumor spread exist but data focusing on lymphangiogenesis are rare.
  • Since the VEGF-C/VEGF-D/VEGFR-2, R-3 axis appears to be the signaling pathway for tumor-induced lymphangiogenesis and an attractive target for therapeutic intervention; we analyzed the expression and the presence of the soluble forms in 30 RCC patients and results were correlated with clinicopathological parameters.
  • METHODS: Tumor and sera from 30 RCC patients (20 clear cell (ccRCC)&10 papillary (pRCC) were included in this study.
  • The expressions of VEGFR-2,R-3 &VEGF-C,-D expressions on tumor were evaluated by immunohistochemestry.
  • Therefore, further studies are necessary to determine if lymphangiogenesis can play a role as a prognostic tool or a target for therapeutic intervention in renal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963428.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Takeda A: Use of anti-neuropilin 1, 2 antibodies to predict colorectal cancer prognosis. J Clin Oncol; 2009 May 20;27(15_suppl):e15111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of anti-neuropilin 1, 2 antibodies to predict colorectal cancer prognosis.
  • : e15111 Background: Neuropilin (NRP) was initially described as non-tyrosine kinase receptors for neuron guidance factor belonging to the Semaphorin family.
  • Neuropilins are widely expressed not only normal developing tissues but also several types of tumor cells.
  • It was reported that the expression of NRP-1 is increased by VEGF, mediated through VEGFR-2, which correlates with tumor growth and invasiveness in colorectal cancer.
  • NRP-2 knockout mice studies showed marked deficits in the development of small lymphatic vessels and its function was associated with the formation of lymphatic network, but the role of NRP-2 in colorectal cancer remains unknown.
  • In recent study, we have analyzed the expression of NRP-1 and NRP-2 in some cultured cell lines by western blot and the clinicopathological significance in colorectal cancer.
  • NRP-1 and NRP-2 gene expression was evaluated by RT- PCR, which was compared with immunohistochemical examination of colorectal cancer tissues.
  • The expression of NRP-1 showed apparent correlation with liver metastasis (p=0.027) and venous invasion (p=0.0025), while NRP-2 expression was correlated with lymph node metastasis (0.001) and lymphatic invasion (0.039) by immunohistochemical analysis.
  • CONCLUSIONS: These results suggest that NRP-1 acts as angiogenesis factor and NRP-2 acts lymphangiogenesis factor, both of them are useful predictive marker in colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960860.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Tsubamoto H, Wada R, Kanazawa R, Komori S, Maeda H, Hirota S, Adachi S: Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16518
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16518 Background: Adenocarcinoma (including adenosquamous carcinoma) of the uterine cervix has a tendency to early lymph node metastasis and is resistant to radiation therapy, thus results in poor prognosis compared with squamous cell carcinoma.
  • Primary endpoints were clinical and pathological responses, and secondary endpoints were toxicities, relapse free survival (RFS) and overall survival (OS).
  • Clinical response rate (RR: CR+PR) of the patients with stage IB2-IIB was 100%.
  • 16 of 17 received RH, and no residual malignant cells were found pathologically (pCR) in 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Brown J, Deavers MT, Nick AM, Milojevic L, Gershenson DM, Sood AK: Clinical relevance of angiogenesis and lymphangiogenesis in patients with sex cord-stromal ovarian tumors. J Clin Oncol; 2009 May 20;27(15_suppl):5575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5575 Background: Distant metastasis is common in patients with sex cord-stromal ovarian tumors (SCSTs), but lymph node involvement is extremely rare.
  • METHODS: After Institutional Review Board approval, 80 tumor samples (46 primary, 34 recurrent) were obtained from 65 patients and stained for CD31 (microvessel density; MVD), D2-40 (lymphvascular density; LVD), and VEGF.
  • While VEGF expression was not related to the pattern of recurrence, high MVD was strongly associated with distant metastasis (abdomen, liver, lung, bone) compared with local recurrence (p < 0.001).
  • Lymph node metastasis was clinically evident in only 3 of the 65 patients.
  • Interestingly, all 3 tumors with nodal metastasis had significantly greater LVD (LVD = 35.8 vessels/hpf) compared to those without nodal metastasis (LVD = 2.7 vessels/hpf; p < 0.001).
  • Most of these tumors have poor lymphatic development that might explain the low likelihood of nodal metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962605.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Yoshii T, Tamai S, Aoyama N, Minamide J, Takagi S, Motohashi O, Nakayama N, Nishimura K, Takata K, Kameda Y: Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15569
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer.
  • : e15569 Background: When a tumor invades to the muscularis mucosa or submucosal layer (T1a-MM or T1b, in Japan), cSt I esophageal cancer(EC) has 10-50%.
  • risk of lymph node metastasis (LNM).
  • 5 developed LNM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962323.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Brahmer JR, Topalian SL, Powderly J, Wollner I, Picus J, Drake CG, Stankevich E, Korman A, Pardoll D, Lowy I: Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3018
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This expansion cohort in a phase I/II trial of MDX-1106, a fully human IgG4 antibody blocking PD-1, sought to further evaluate the safety and activity of the 10 mg/kg dose.
  • METHODS: Patients (pts) with treatment refractory metastatic non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colon cancer (CC), melanoma (MEL), or prostate cancer (CRPC), and no history of autoimmune disease received a single infusion of MDX-1106 at 10 mg/kg.
  • Those with PR/CR were observed without retreatment.
  • One pt with RCC had a PR after 3 doses, lasting 5+ months (mo).
  • Biopsy of a regressing MEL lymph node metastasis showed a moderately increased and selective CD8+ T cell infiltrate post treatment.
  • Analyses of circulating lymphocyte subsets and tumor B7-H1 expression are in progress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962055.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Huguet F, Gratacap M, Ménard J, Perie S, Angelard B, Jafari A, Pène F, Torti F, Touboul E, Lacau St Guily J: Alternative therapeutic approaches after induction chemotherapy for tonsil squamous cell carcinomas. J Clin Oncol; 2009 May 20;27(15_suppl):e17010
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After surgery, 69 pts received a dose of 50 to 70 Gy on the primary site depending on pathological findings (Group 1).
  • Sixteen pts with negative margins and no lymph node metastasis didn't receive any EBRT (Group 2).
  • After ICT, pathological complete response was observed in 18 pts (25%) for the primary site and 20 pts (34%) for lymph nodes.
  • In the Group 2, 6 pts had a relapse, among them 4 had EBRT in a second time.
  • CONCLUSIONS: Pts with a complete pathological response after ICT who were not irradiated had a non significant increase of the relapse rate with a specific survival identical to the group of irradiated pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961737.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Tanaka M, Sethi S, Li D, Bland G, Hamilton SR, Abbruzzese JL, Eng C: CHFR methylation as an epigenetic marker for recurrence of colon cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4043
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHFR methylation as an epigenetic marker for recurrence of colon cancer.
  • : 4043 Background: Currently, no definitive epigenetic markers exist to predict recurrence and overall survival (OS) of colorectal cancer patients after surgical resection.
  • Promoter hypermethylation of the ID4 (inhibitor of DNA binding), RECK (reversion-inducing cysteine rich protein with Kazal motifs), and CHFR (checkpoint with forkhead-associated and RING finger domains) genes have been associated with reduced mRNA and protein expression in colorectal cancer.
  • The purpose of this study was to determine the association of methylation of these genes and also MINT1 (methylated in tumor loci) with recurrence-free survival (RFS) and OS in colon cancer patients.
  • METHODS: DNA methylation was quantitatively evaluated using pyrosequencing in tissue samples from 64 patients with AJCC stage II and III colon cancer without HNPCC seen at M.D.
  • CONCLUSIONS: The presence of high CHFR promoter methylation correlates with advanced lymph node metastasis and shortened RFS and OS.
  • Methylation of the CHFR promoter is a potential epigenetic marker for colon cancer recurrence and overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961567.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Dos Santos L, Garg K, Diaz JP, Soslow RA, Hensley ML, Alektiar KM, Barakat RR, Leitao MM Jr: Incidence of adnexal and lymph node metastases in endometrial stromal sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):5589
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of adnexal and lymph node metastases in endometrial stromal sarcoma.
  • : 5589 Background: To determine the incidence of adnexal and lymph node (LN) metastases in endometrial stromal sarcoma (ESS).
  • METHODS: We identified all cases evaluated at our institution with a diagnosis of ESS from January 1, 1980 to December 31, 2007.
  • Adnexal metastases were identified in 8 (9.5%) of 84 cases.
  • All adnexal metastases were manifested by gross adnexal tumor and occurred in patients with other gross pelvic extrauterine disease.
  • Seven of these 8 patients also had lymph-vascular space invasion (LVSI).
  • In patients with gross pelvic extrauterine disease, adnexal metastasis did not affect survival.
  • LN metastases were identified in 8 (24%) of the 34 patients who underwent LN evaluation.
  • Five of the 8 cases with LN metastases had LVSI.
  • Of 20 patients with disease grossly limited to the uterus and grossly normal LN, 2 (10%) had LN metastases.
  • Four of the remaining 6 patients with LN metastases had grossly positive LN and other gross extrauterine disease.
  • CONCLUSIONS: The incidence of LN metastases in ESS is most commonly associated with gross extrauterine disease, extensive myoinvasion and LVSI.
  • The rate of adnexal metastasis appears to be negligible in the absence of gross adnexal and extrauterine tumor, but there may be a role for oophorectomy in the hormonal management of ESS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Yu DH, Zhong X, Mu D, Fu Z, Zhang B, Zhang L, Zhang W: Compare the diagnostic value of FLT and FDG PET/CT in assessment of regional lymph nodes in thoracic esophageal squamous cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15620
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compare the diagnostic value of FLT and FDG PET/CT in assessment of regional lymph nodes in thoracic esophageal squamous cell carcinoma.
  • : e15620 Background: To determine whether FLT PET/CT can detect regional lymph nodes metastases in untreated thoracic esophageal squamous cell carcinoma.
  • The results of reviewing side-by-side FDG PET/CT and FLT PET/CT images for the diagnosis of locoregional lymph node metastases were compared prospectively in relation to pathologic findings.
  • The differential threshold for malignancy was set as SUV<sub>FDG</sub>≥2.5, and SUV<sub>FLT</sub>≥1.4, respectively.
  • RESULTS: All patients underwent esophagectomy and lymphadenectomy, and pathologic examination confirmed nodes positive for metastasis in 14 patients and 42 of 344 excised nodes.
  • The uptake of FDG (median SUVmax, 5.59; range, 2.5-10.6) in locoregional lymph nodes metastasis was significantly higher than that of FLT (median SUVmax, 2.93; range, 1.6-4.6).
  • There were 14 false positive nodes in FDG PET and only 3 in FLT PET, 7 false negative nodes in FDG PET, while 11 false negative nodes in FLT PET.
  • CONCLUSIONS: FLT uptake in regional lymph node of esophageal carcinoma is significantly lower compared with FDG uptake.FLT PET has fewer false-positive findings compared with FDG PET.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS: Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res; 2009 Dec;2(6):317-323
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The records of the patients were reviewed and the prognostic factors such as age, gender, location and size of the tumor, type of surgery, blood transfusion, depth of tumor invasion, lymph node metastases, stage of the disease, grading, vascular invasion, lymph vessel invasion, characteristics of the tumor according to Lauren's classification, and lymph node ratio were evaluated by using statistical methods.
  • RESULTS: In a total of 12 patients (24%) major morbidities developed, and five patients (10%) died.
  • Lymph node metastases (P = 0.03), lymph vessel invasion (P = 0.001), blood transfusion (P = 0.021), and lymph node ratio (P = 0.006) were the prognostic features identified by univariate analysis.
  • Among the multiple significant prognostic factors in the univariate analysis only one factor, lymph node ratio, proved to be independently significant in the multivariate analysis (RR: 4.47).
  • CONCLUSIONS: Our data showed that we can expect a good survival for patients with a lymph node ratio less than 0.2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990200.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Advanced / Gastric Cancer / Morbidity / Mortality / Survival / Transmural
  •  go-up   go-down


66. French AJ, Sinicrope F, Foster NR, Thibodeau SN, Sargent DJ, O'Connell MJ: Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers. J Clin Oncol; 2009 May 20;27(15_suppl):11093
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: TNM stage II and III colon carcinomas (n= 982) were studied from six 5- fluorouracil-based adjuvant therapy trials conducted by the North Central Cancer Treatment Group.
  • Logistic regression and a recursive partitioning and amalgamation (RPA) analysis was used to identify important predictive factors of MMR status.
  • Factors explored included age, gender, histologic grade, tumor site, stage, lymph node metastases, and T-stage.
  • Tumor site was the most important predictor of MMR status followed by histologic grade.
  • Using tumor site, histologic grade, and gender, the logistic regression model showed excellent discrimination (c- statistic = 0.81).
  • CONCLUSIONS: Tumor site is an important predictor of defective MMR that is rare in distal and increased in proximal tumors.
  • The combination of proximal site, poor differentiation, and female gender resulted in a 51% likelihood of defective MMR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Saha S, Sirop S, Korant A, Chakravarty B, Krishnaiah N, Wiese D, Soni M, Arora M, Nagpal S, Singh T: The number of lymph node metastases as a prognostic indicator of disease-specific survival in the era of sentinel lymph node mapping in colon cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of lymph node metastases as a prognostic indicator of disease-specific survival in the era of sentinel lymph node mapping in colon cancer.
  • : e15000 Introduction: Sentinel Lymph Node Mapping (SLNM) in colon cancer (CCa) is shown to be successful, sensitive and accurate.
  • We aimed to evaluate the survival of patients (pts) undergoing SLNM in addition to the standard colon resection, compare it to pts without SLNM and correlate it to the number of LN metastasis.
  • The primary outcome was cancer-specific survival.
  • Exclusion criteria were stage IV disease, 2nd malignancy, or lost to F/U.
  • Cancer specific survival of gpA was then analyzed according to the number of positive LNs.
  • In 15.1% of node +ve pts, the disease was upstaged because of micrometastasis (0.2-2mm).
  • The 5 year-cancer specific survival of pts in gpA vs gpB was 100% vs 94.9% in stage I, 91.2% vs 83.5% in stage II and 81.8% vs 63% in stage III disease.
  • For gpA pts, the 5 year cancer-specific survival decreased from 95.0% in node -ve disease to 92.8% when 1 LN was +ve, 83.3% when 2 LNs were +ve and 71.4% when 3 or more LNs were +ve (Table).
  • CONCLUSIONS: A significant number of pts with CCa are being upstaged and the true node -ve disease is being identified when SLNM is performed at the time of surgery leading to improved survival as compared to conventional surgery.
  • Our study showed that the number of LN metastasis is a predictor of cancer specific survival even after SLNM in CCa.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964385.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Arora ML, Saha S, Sirop S, Chakravarty B, Korant A, Soni M, Wiese D, Desai D, Ganatra B, Kaushal S, Iddings D: The impact of the number of lymph node metastases on the overall recurrence of colon cancer in the era of sentinel lymph node mapping. J Clin Oncol; 2009 May 20;27(15_suppl):4049
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the number of lymph node metastases on the overall recurrence of colon cancer in the era of sentinel lymph node mapping.
  • : 4049 Background: Sentinel Lymph Node Mapping (SLNM) in colon Cancerc (Cca) has been shown to be successful, sensitive and accurate.
  • METHODS: Between 1996 and 2006, pts diagnosed with Cca were enrolled in a prospective trial and underwent SLNM and oncologic resection including regional LNs.
  • For recurrence analysis, exclusion criteria included: stage IV disease, benign pathology, lost to follow-up, refusal of indicated chemotherapy, non cancer related death or second cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961561.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Espino-Strebel E, Luna JT: Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16524
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer.
  • : e16524 Background: Poor prognostic factors dictating the need for extended surgical staging among endometrial cancer patients can be accurately determined only after laparotomy.
  • This prospective study was conducted to determine the correlation between preoperative serum CA125 and surgicopathologic prognostic factors in endometrial cancer.
  • METHODS: Endometrial cancer patients diagnosed from October 2006 to July 2008 who were eligible for primary surgical treatment were included.
  • All patients underwent laparotomy, peritoneal fluid cytology, extrafascial/radical hysterectomy, bilateral salpingooophorectomy, bilateral pelvic lymph node dissection, and para-aortic lymph node sampling.
  • Specimens were examined for tumor differentiation, lymphovascular space invasion, depth of myometrial invasion, cervical, adnexal, and vaginal involvement, pelvic and para-aortic lymph node metastases, and peritoneal fluid cytology.
  • Preoperative serum CA125 was significantly correlated with deep myometrial invasion (p = 0.02), adnexal metastasis (p = 0.01), pelvic (p < 0.01), and para-aortic node involvement (p<0.01).
  • CONCLUSIONS: Preoperative serum CA125 has a significant correlation with deep myometrial invasion, adnexal metastasis, pelvic and para-aortic lymph node involvement, and extrauterine disease at a cutoff value of 55U/mL.
  • It is recommended that serum CA125 determination be part of the preoperative work-up of endometrial cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Fyles A, Pintilie M, Hedley D, Bristow R, Wouters B, Hill R, Milosevic M: High interstitial fluid pressure (IFP) and hypoxia as biomarkers of cisplatin chemoradiation response in advanced cervix cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5584
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High interstitial fluid pressure (IFP) and hypoxia as biomarkers of cisplatin chemoradiation response in advanced cervix cancer.
  • : 5584 Background: Chemoradiotherapy (CRT) has been shown to improve survival compared to RT alone for locally advanced cervix cancer.
  • The tumour microenvironment in cervix cancer is also known to influence disease progression and response to treatment.
  • In this prospective study, pre-treatment tumour hypoxia and interstitial fluid pressure (IFP) were examined as potential biomarkers of improved treatment effectiveness in a cohort of patients treated with definitive radiation alone, or with the addition of concurrent cisplatin CRT.
  • METHODS: Between April 1994 and January 2006, 309 eligible patients with cervix cancer were entered into a prospective study of hypoxia and IFP prior to definitive treatment.
  • Clinical characteristics were similar between the two cohorts except pelvic lymph node metastases were more frequent in the CRT cohort (42% vs. 19%, p = 0.0005), likely due to changes in definition of positive nodes on CT or MR imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962393.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Jueckstock JK, Scholz C, Brandelik A, Rack BK, Sommer HL, Janni WJ, Friese K: Effect of social or health insurance status on outcome of patients with early breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6609
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of social or health insurance status on outcome of patients with early breast cancer.
  • : 6609 Background: Recent studies in the US showed a relationship between state of social or health insurance of cancer patients and their overall survival (OAS). ([1] Banerjee M et al, Cancer. 2007;110:2169-2177.
  • [2] Griggs JJ et al, J Clin Oncol. 2007;25:2522-2527.
  • [3] Brookfield KF et al, Cancer. 2008.
  • METHODS: In a retrospective analysis of 1846 German early breast cancer pts correlation between state of social and health insurance and OAS was investigated.
  • Age, tumor size, lymph node metastases, and tumor grading were well balanced between the two groups.
  • RESULTS: OAS as expected was strongly correlated to established prognostic factors like age, tumor size, lymph node status, and grading (p < 0.001 respectively).
  • CONCLUSIONS: Unlike the American results there was no correlation seen between state of social or health insurance for German early breast cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961739.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Dulala R, Campian JL, Dubner S, Frank D, Gabalski E, Thomas A, Akerman M, Mehrotra B: Evaluation of PET imaging in treatment decision making for early stage head and neck squamous cell cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17017
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of PET imaging in treatment decision making for early stage head and neck squamous cell cancer.
  • However, the role of PET scan in pts. with early stage disease and clinically negative nodes remains controversial.
  • Eligibility criteria included: clinically staged T1N0, documented pre-operative PET scans and primary surgical management including a neck lymph node dissection as part of initial treatment.
  • Twelve of sixty six pts met eligibility criteria for this study.
  • Primary sites of tumor were: tongue (n = 8) 67%; oral cavity (n = 3) 25%; larynx (n = 1) 8%.
  • Additionally, PET positivity was noted in regional lymph node sites in six of twelve pts.
  • Operative pathology confirmed tumor presence in all primary sites.
  • Median numbers of lymph nodes dissected were 25 (range:13-34).
  • Based on these clinical data, the calculated statistical parameters for preoperative PET scan in detecting occult neck lymph node metastases were: negative predictive value: 100%; positive predictive value: 50%: specificity: 50%; sensitivity: 0%.
  • A high negative predictive value suggests that a negative result can exclude metastatic lymph nodes involvement in this group of pts. with early stage disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961705.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Chien NC, Lin CW, Tzeng JE: Sclerosing haemangioma with lymph node metastasis. Respirology; 2009 May;14(4):614-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing haemangioma with lymph node metastasis.
  • Sclerosing haemangioma (SH) of the lung is an intrapulmonary tumour composed of polygonal and cuboidal cells arranged in a heterogeneous pattern.
  • SH is generally regarded as benign or very low-grade; only rarely have cases of lymph node metastasis been reported.
  • We report a case of SH with metastasis to the regional lymph nodes in an 18-year-old male, whose left lung tumour was identified incidentally on routine CXR.
  • The left upper lobe was removed and the regional lymph nodes dissected.
  • The tumour consisted of proliferative cuboidal and polygonal cells arranged in a papillary pattern within the sclerotic stroma.
  • Subcapsular metastasis was observed in a lymph node.
  • SH with lymph node metastasis was diagnosed.
  • Lobectomy with nodal dissection is suggested for the treatment of pulmonary SH, especially in the case of large tumours with enlargement of regional lymph nodes.
  • Investigation of more cases and long-term follow up are necessary to assess the clinical significance of lymph node metastasis.
  • [MeSH-major] Histiocytoma, Benign Fibrous / secondary. Histiocytoma, Benign Fibrous / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402838.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


74. Wang JF, Dai DQ: [Methylation of PTPRG gene and its regulation in gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2008 Feb;30(2):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Methylation of PTPRG gene and its regulation in gastric cancer].
  • OBJECTIVE: To investigate the difference in methylation of PTPRG gene between gastric primary cancer and its lymph node metastases, and its regulation by 5-Aza-2'-deoxycytidin in a gastric cancer cell line SGC7901.
  • METHODS: Methylation-specific polymerase chain reaction (MSP) and RT-PCR were applied to identify the difference between gastric primary cancer and lymph node metastases and assess the changes of methylation in gastric cancer cell line SGC7901 treated by 5-Aza-2'-deoxycytidin.
  • RESULTS: There were significant differences of PTPRG gene methylation and PTPRG mRNA expression between gastric primary cancer and lymph node metastases: a linear regression analysis revealed a significant association between the quantity of metastatic lymph nodes and their methylation rate.
  • PTPRG gene methylation in the gastric cancer cell line changed into negative and PTPRG mRNA expression in the cell line was recovered after 5-Aza-2'-deoxycytidin treatment.
  • CONCLUSION: There is a difference of PTPRG gene methylation in gastric primary cancer and metastatic lymph nodes.
  • [MeSH-major] Azacitidine / analogs & derivatives. DNA Methylation. Lymph Nodes / metabolism. Receptor-Like Protein Tyrosine Phosphatases, Class 5 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA Modification Methylases / antagonists & inhibitors. Gene Expression Regulation, Neoplastic / drug effects. Humans. Lymphatic Metastasis. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646686.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; EC 3.1.3.48 / PTPRG protein, human; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5; M801H13NRU / Azacitidine
  •  go-up   go-down


75. Nasu J, Nishina T, Hirasaki S, Moriwaki T, Hyodo I, Kurita A, Nishimura R: Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers. J Clin Gastroenterol; 2006 May-Jun;40(5):412-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers.
  • BACKGROUND: For intramucosal differentiated early gastric cancer that has little risk of lymph node metastasis, local treatment such as endoscopic mucosal resection has been generally accepted as an adequate treatment.
  • We studied clinicopathological characteristics of undifferentiated early gastric cancer at our institution to identify the predictive factors for lymph node metastasis and qualify lesions that should be referred for gastrectomy and not endoscopic mucosal resection.
  • METHODS: We retrospectively analyzed the clinicopathological features (patient age and gender, tumor size, location, macroscopic type and histological type, presence of ulceration, depth of tumor invasion, and lymphatic-vascular involvement) in 332 patients with undifferentiated early gastric cancer who underwent gastrectomy with regional lymph node dissection.
  • RESULTS: Lymph node metastasis was observed in 45 patients (14%).
  • Univariate analysis revealed that depth of tumor invasion (submucosa), tumor size (>30 mm), and lymphatic-vascular involvement (positive) were associated with lymph node metastasis.
  • CONCLUSIONS: Lymphatic-vascular involvement was the only independent predictive risk factor for lymph node metastasis.
  • This pathologic factor was not useful for identifying patients at high risk of lymph node metastasis who should be offered gastrectomy rather than endoscopic mucosal resection.
  • [MeSH-major] Lymphatic Metastasis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Gastrectomy. Gastroscopy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721222.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Al Habeeb A, Weinreb I, Ghazarian D: Primitive non-neural granular cell tumour with lymph node metastasis. J Clin Pathol; 2009 Sep;62(9):847-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive non-neural granular cell tumour with lymph node metastasis.
  • Primitive non-neural granular cell tumour (PNGCT) is a rare tumour of uncertain lineage.
  • This report describes a case of PGNCT with lymph node metastasis.
  • This is thought to be only the second reported case with lymph node involvement.
  • [MeSH-major] Granular Cell Tumor / pathology. Granular Cell Tumor / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Buttocks. Female. Humans. Lymphatic Metastasis. Pregnancy. Pregnancy Complications, Neoplastic / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734486.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Ma Y, Zhu G, Xue Y, Zhang Y, Zhang M: Extreme analysis of risk factors for lymph node metastasis in gastric cancer. Hepatogastroenterology; 2010 Mar-Apr;57(98):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extreme analysis of risk factors for lymph node metastasis in gastric cancer.
  • BACKGROUND/AIMS: The accurate diagnosis of lymph node metastasis is necessary in gastric cancer.
  • This study was carried out to identify the risk factors of lymph node metastasis by extreme analysis.
  • METHODOLOGY: Data from 77 patients with lymph node-positive small gastric cancer and 128 patients with lymph node-negative large gastric cancer were collected.
  • The independent risk factors influencing lymph node metastasis were determined by multiple logistic regression analysis.
  • RESULTS: Rural residence, introversive personality, low third gastric cancer, low serum fibrinogen content, serosal invasion, and high serum CEA level were found to be associated with lymph node metastasis.
  • The rural residence, introversive personality, serosal invasion, and high serum CEA level were the independent risk factors for lymph node metastasis in the multivariate logistic regression model.
  • CONCLUSIONS: Rural residence, introversive personality, serosal invasion, and high serum CEA level were significantly and independently related to lymph node metastasis.
  • The limited surgery with potentially incomplete lymph node dissection is not recommended in gastric cancer patients with these risk factors.
  • [MeSH-major] Lymph Nodes / pathology. Lymphatic Metastasis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Biomarkers, Tumor. Female. Gastrectomy. Humans. Lymph Node Excision. Male. Middle Aged. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583444.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Shan Y, Zhao DB, Che X, Wang JX, Shao YF, Zhao P: [Clinical significance of solitary lymph node metastasis in carcinoma of the ampulla of Vater]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):694-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of solitary lymph node metastasis in carcinoma of the ampulla of Vater].
  • OBJECTIVE: To investigate the rule of distribution of solitary lymph node metastasis and its relation with clinico-pathologic factors in carcinoma of ampulla of Vater.
  • METHODS: The data of 26 patients who were discovered to have solitary lymph node metastasis, from 152 patients with carcinoma of the ampulla of Vater who had received pancreatoduodenectomy were retrospectively reviewed.
  • The related clinico-pathologic factors affecting it's metastasis were analyzed and compared with 105 such patients without any lymph node metastasis.
  • 9%) had lymph node metastasis and 26 had only solitary lymph node metastasis with a rate of solitary lymph node metastasis of 55.
  • 3% (26/47). The majority of the solitary lymph node metastasis (84.
  • 6% , 22/26) were located at the pancreaticoduodenal region, only 4 patients had skip metastasis.
  • It was revealed by Chi-square test (chi(2) ) that solitary lymph node metastasis was correlated with the tumor size (P = 0.
  • CONCLUSION: The majority of solitary lymph node metastasis are located at the pancreaticoduodenal region.
  • Sentinel lymph node assessment may be helpful to determine the extent of lymph node dissection for carcinoma of the ampulla of Vater.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatic Neoplasms / pathology. Pancreaticoduodenectomy. Retrospective Studies. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274378.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


79. Chen Z, Yan JJ, Huang L, Wu MC, Yan YQ: [Lymph node metastasis of patients with intrahepatic cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2006 Apr 1;44(7):454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymph node metastasis of patients with intrahepatic cholangiocarcinoma].
  • OBJECTIVE: To investigate the relationship between lymph node metastasis and prognosis in patients of intrahepatic cholangiocarcinoma (ICC).
  • Logistic regression analysis was performed to determine the factors influencing lymph node metastasis and log-rank univariate analysis was used to assess the role of lymph node metastasis in the long-survival.
  • RESULTS: Lymph node metastasis in hepatoduodenal ligament could be detected in all 29 preoperative and 48 postoperative lymph metastatic cases, without "jumping-metastasis".
  • Lymph metastasis was one of the major causes of postoperative mortality, and resulted in 36 of 58 followed-up death postoperatively.
  • According to logistic analysis, pathological types of the carcinoma (chi(2) = 4.071, P = 0.044) and periductal-infiltrating tumors (chi(2) = 3.872, P = 0.037) were significant predictors of lymph node metastasis.
  • CONCLUSIONS: Lymph nodes in the hepatoduodenal ligament may be sentinel nodes for ICC lymph node metastasis.
  • Aggressive treatment of lymph node metastasis in the hepatoduodenal ligament is an important strategy to improve the long-survival of postoperative ICC patients.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / secondary. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772078.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Ohashi S, Okamura S, Urano F, Maeda M: Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer. Gastric Cancer; 2007;10(4):241-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer.
  • BACKGROUND: We aimed to elucidate clinicopathological variables associated with lymph node metastasis of submucosal invasive gastric cancer.
  • METHODS: Specimens were surgically resected from 201 patients who had primary submucosal gastric cancer.
  • We studied 39 consecutive patients with lymph node metastasis and 162 patients without lymph node metastasis.
  • We compared the following clinicopathological characteristics of the patients in relation to lymph node metastasis: age, sex, tumor size, histology, extent of submucosal invasion, lymphatic and venous invasion, and ulceration of the tumor.
  • We also studied the relationship between lymph node metastasis of submucosal gastric cancer and immunohistochemistry for p53, Ki67, vascular endothelial growth factor (VEGF), alpha-fetoprotein, sLe(a), and dendritic cells (DCs).
  • RESULTS: In terms of conventional pathological factors, lymph node metastasis in submucosal gastric cancer was related to tumor size (P = 0.002), depth of submucosal invasion (P = 0.001), lymphatic invasion (P < 0.0001), and venous invasion (P = 0.012).
  • Lymph node metastasis in sm1 gastric cancer was significantly related to VEGF expression (P = 0.047).
  • Also, lymph node metastasis in sm3 gastric cancer was significantly correlated with DC expression (P = 0.016).
  • Multivariate analysis showed that tumor size, tumor invasion depth in the submucosal layer, and lymphatic invasion were independent predictors of nodal metastasis in submucosal gastric cancer.
  • CONCLUSION: Conventional pathological factors, such as tumor size, depth of submucosal invasion, and lymphatic invasion, have a significant influence on lymph node metastasis.
  • VEGF expression and DC expression may be helpful predictors of lymph node metastasis in patients with sm1 and sm3 gastric cancer, respectively.
  • [MeSH-minor] Aged. Biomarkers / metabolism. Dendritic Cells / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095080.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


81. Morita H, Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Nishimura C, Igarashi Y, Miki K, Ishii T: Histopathological predictor for regional lymph node metastasis in gastric cancer. Virchows Arch; 2009 Feb;454(2):143-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological predictor for regional lymph node metastasis in gastric cancer.
  • Regional lymph node metastasis in gastric cancer is a definitive indicator of the patient's prognosis.
  • The goal of this study was to identify the predictors for lymph node metastasis among all the possible histopathological parameters, especially by conducting an objective discrimination of the lymphatic and blood vessels.
  • A total of 210 resected primary gastric cancers with or without lymph node metastasis were evaluated based on the conventional histopathological parameters together with immunohistochemistry using antisera-recognizing lymphatic endothelial hyaluronan receptor-1 (LYVE-1), von Willebrand factor, and lymphangiogenesis promoter vascular endothelial growth factor-C (VEGF-C) antibodies.
  • A multivariate regression analyses of the results indicated that only lymphatic invasion was a significant independent predictor of lymph node metastasis at any stage of cancer invasion.
  • VEGF-C expression was partially related to lymph node metastasis in early gastric cancer.
  • The identification of lymphatic invasion by LYVE-1 antibody is therefore useful to predict regional lymph node metastasis in gastric cancer.
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Logistic Models. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Vascular Endothelial Growth Factor C / analysis. Vesicular Transport Proteins / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104832.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / LYVE1 protein, human; 0 / Vascular Endothelial Growth Factor C; 0 / Vesicular Transport Proteins
  •  go-up   go-down


82. Li JD, Wang WG, Xu JL, Gao ZR, Shao LF: [Characteristics of lymph node metastasis in thoracic esophageal carcinoma]. Zhonghua Yi Xue Za Zhi; 2006 Dec 5;86(45):3197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of lymph node metastasis in thoracic esophageal carcinoma].
  • OBJECTIVE: To investigate the frequency, distribution, and feature of lymph node metastasis in thoracic esophageal carcinoma, and to provide evidence for lymph node dissection and the multidisciplinary therapy for patients with esophageal carcinoma postoperatively.
  • METHODS: The clinical data of 623 patients with thoracic esophageal carcinoma who had undergone esophagectomy plus lymph node dissection were studied to analyze the characteristics of lymph node metastasis.
  • RESULTS: Totally 3689 of lymph node groups (with 8603 nodes) were dissected.
  • The lymph node metastasis rate was 47.2% and lymph node metastasis ratio was 10.3%.
  • No lymph node metastasis was found in the patients of Tis stage, while lymph node metastasis was found in the patients of other stages.
  • There were significantly differences in lymph node metastasis rate and ratio among the patients of different T stages (chi2 = 38.407, P = 0.00, and chi2 = 118.438, P = 0.000).
  • The higher the T stage, the higher the lymph node metastasis rate and ratio (r = 1, P = 0.000, and r = 1, P = 0.000).
  • Different pathological types of esophageal carcinoma had different lymph node metastasis ratio (chi2 = 84.577, P = 0.000), however, there was no significant difference in lymph node metastasis rate among different pathological types (chi2 = 6.284, P = 0.179).
  • The patients with squamous carcinoma had the lowest lymph node metastasis ratio and lymph node metastasis rate.
  • The lymph node metastasis was mainly regional and extended vertically in both directions.
  • Leaping over metastasis was another feature.
  • All segments of thoracic esophageal carcinoma, especially lower thoracic esophageal carcinoma, could metastasize to the celiac lymph nodes.
  • CONCLUSION: Lymph node dissection should be carried out properly in treatment of esophageal carcinoma and regional celiac lymph nodes should be explored and dissected more cautiously.
  • Because surgical treatment is relatively radical in treatment of esophageal carcinoma, and taking the trend of lymph node metastasis and other indication into account, rational multidisciplinary therapy conducted as soon as possible should be adopted in the treatment of esophageal carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Thorax

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313786.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Liang P, Hong JW, Ubukata H, Liu G, Katano M, Motohashi G, Kasuga T, Watanabe Y, Nakada I, Tabuchi T: Myofibroblasts correlate with lymphatic microvessel density and lymph node metastasis in early-stage invasive colorectal carcinoma. Anticancer Res; 2005 Jul-Aug;25(4):2705-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myofibroblasts correlate with lymphatic microvessel density and lymph node metastasis in early-stage invasive colorectal carcinoma.
  • BACKGROUND: Recent studies have shown that the interactions between tumor cells and stromal cells are important in tumor development.
  • A possible correlation between tumor-activated myofibroblasts, the main component cells of tumor stroma, and lymphatic microvessel density (LMVD) or other clinical parameters in carcinoma was investigated.
  • Increased PMpt was also associated with lymphatic invasion (p = 0.0051) and with lymph node metastasis (p = 0.011).
  • CONCLUSION: Proliferation of myofibroblasts in peri-tumoral areas seem to play an important role in lymphangiogenesis, and is also associated with lymph node metastasis.
  • [MeSH-minor] Actins / biosynthesis. Adult. Aged. Aged, 80 and over. Female. Fibroblasts / metabolism. Fibroblasts / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Membrane Glycoproteins / biosynthesis. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080515.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  •  go-up   go-down


84. Xue HC, Wu CR, Zhang ZB, Zhu ZH, Ma ZK, Gao J: [Regulations and lymphadenectomy strategy of mediastinal and upper abdominal lymph node metastasis in thoracic esophageal carcinoma]. Ai Zheng; 2007 Sep;26(9):1020-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regulations and lymphadenectomy strategy of mediastinal and upper abdominal lymph node metastasis in thoracic esophageal carcinoma].
  • BACKGROUND & OBJECTIVE: Regional lymph node metastasis plays an important role in the prognosis of esophageal carcinoma.
  • However, the range of lymph node dissection is still controversial.
  • This study was to investigate the regulations of lymph node metastasis of thoracic esophageal carcinoma in the mediastinum and upper abdomen, and explore the rational lymphadenectomy with Ivor-Lewis procedure.
  • The regulations of regional lymph node metastasis were analyzed.
  • RESULTS: Of the 1,412 patients, 323 (22.88%) had postoperative complications, 2 (0.14%) died during hospitalization, and 547 (38.74%) had lymph node metastasis.
  • The lymph node metastasis rates were 32.30% in the right para-trachea triangle, 18.43% in the upper mediastinum, 5.31% in the lower mediastinum, and 17.28% in the upper abdomen(P<0.001).
  • Of the 13 916 resected lymph nodes, 2 662 (19.13%) were positive; the metastasis degree (positive lymph nodes/resected lymph modes) were 23.83% in the right para-trachea triangle, 18.92% in the upper mediastinum, 21.07% in the lower mediastinum, and 17.20% in the upper abdomen.
  • For those patients with the cancer focuses in the upper, middle and lower segments of the esophagus, the lymph node metastasis rates were 40.59%, 36.97% and 44.35% (P=0.093), respectively, while the lymph node metastasis degree in these 3 fields were 19.60%, 18.35%, and 21.82%, respectively.
  • Both the lymph node metastasis rate and degree were significantly higher in the patients at advanced stage than in the patients at early stage (46.56% vs. 7.75%, 21.82% vs. 4.01%, P<0.001).
  • CONCLUSIONS: Regional lymph node metastasis, especially in the right para-trachea triangle and upper mediastinum, is a key factor for thoracic esophageal carcinoma.
  • Ivor-Lewis esophagectomy with two-field lymph node dissection is a safe operation for thoracic esophageal carcinoma, and may increase the chances of complete resection.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Lymph Nodes / pathology. Lymphatic Metastasis
  • [MeSH-minor] Abdomen / pathology. Abdomen / surgery. Adult. Aged. Aged, 80 and over. Esophagectomy / methods. Female. Humans. Lymph Node Excision / methods. Male. Mediastinum / pathology. Mediastinum / surgery. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927865.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Wang A, Guo P, Sun Z, Xu H: Clinicopathological variables associated with lymph node metastasis and prognostic factors in pT2 gastric cancer. J Int Med Res; 2009 Mar-Apr;37(2):359-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological variables associated with lymph node metastasis and prognostic factors in pT2 gastric cancer.
  • This retrospective study investigated the clinicopathological variables associated with lymph node metastasis and prognosis in 325 patients with pT2 gastric cancer in order to set out a foundation for the surgical management of this condition.
  • Univariate and multivariate analyses identified factors that were predictive of lymph node metastasis.
  • Tumour location, maximum tumour diameter, lymphatic invasion and total retrieved lymph nodes (tLN) were revealed as independent factors for lymph node metastasis in pT2a gastric cancer, whereas histological type, lymphatic invasion and tLN were associated with lymph node metastasis in patients with pT2b gastric cancer.
  • Maximum tumour diameter, lymphatic invasion and metastatic lymph node (mLN) ratio, but not tLN, were independent prognostic factors in pT2a cancer.
  • Maximum tumour diameter and mLN ratio, but not tLN, were independent prognostic factors in pT2b cancer.
  • Overall, it is concluded that maximum tumour diameter and mLN ratio are important prognostic factors in pT2 gastric cancer.
  • [MeSH-major] Lymphatic Metastasis / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383229.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


86. Yi Kim D, Kyoon Joo J, Kyu Park Y, Yeob Ryu S, Soo Kim H, Kyun Noh B, Hwa Lee K, Hyuk Lee J: E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis. J Surg Oncol; 2007 Oct 1;96(5):429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis.
  • OBJECTIVE: Abnormal expression of E-cadherin plays an important role in the differentiation and progression of gastric carcinoma.
  • However, the relationship between molecular changes in E-cadherin and metastasis in early gastric carcinoma (EGC) is poorly understood.
  • MATERIALS AND METHODS: Sixty cases of EGC with or without lymph node metastasis (30 node-positive cases and 30 node-negative cases) were investigated to evaluate hypermethylation status using bisulfate-MSP and immunohistochemistry using antibody against E-cadherin.
  • RESULTS: Twenty-seven (45.0%) of 60 primary EGCs exhibited methylation in the CpG island of E-cadherin.
  • Abnormal expression of E-cadherin was significantly correlated with patient age, tumor size, Lauren classification, differentiation, and lymph node metastasis.
  • Using multiple logistic regression analysis, two factors were independent, statistically significant parameters associated with lymph node metastasis: abnormal expression of E-cadherin (risk ratio, 2.62; 95% confidence interval, 0.917-7.457; P < 0.05) and lymphatic invasion (risk ratio, 8.11; 95% confidence interval, 1.612-40.766; P < 0.05).
  • CONCLUSION: Our results suggest that methylation of E-cadherin is a frequent, early event in gastric carcinoma progression, and is correlated significantly with downregulated E-cadherin expression.
  • Inactivation of E-cadherin might be involved in metastasis in EGC and play an important role in microscopic differentiation.
  • [MeSH-major] Adenocarcinoma / metabolism. Cadherins / metabolism. Lymphatic Metastasis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. DNA Methylation. Down-Regulation. Female. Humans. Immunohistochemistry. Logistic Models. Male. Middle Aged. Neoplasm Invasiveness. Polymerase Chain Reaction. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786966.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


87. Lee K, Park DJ, Choe G, Kim HH, Kim WH, Lee HS: Increased intratumoral lymphatic vessel density correlates with lymph node metastasis in early gastric carcinoma. Ann Surg Oncol; 2010 Jan;17(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased intratumoral lymphatic vessel density correlates with lymph node metastasis in early gastric carcinoma.
  • BACKGROUND: Prediction of lymph node metastasis in early gastric carcinoma (EGC) is important for management and follow-up of EGC patients.
  • Increased lymphangiogenesis has been suggested to correlate with lymphatic invasion and lymph node metastasis in various tumors.
  • RESULTS: The mean value of intratumoral LVD in a lymph-node-positive EGC group was 28.24/field, which was significantly higher than in a lymph-node-negative EGC group (19.43/field, P = 0.005).
  • Peritumoral LVD, intratumoral MVD, and peritumoral MVD did not correlate with lymph node metastasis in EGCs (P > 0.05).
  • Intratumoral LVD did not show significant differences according to lymphatic invasion and differentiation, which were positive predictors for lymph node metastasis in EGC.
  • Using multivariate logistic regression, intratumoral LVD was an independent factor, with the above two factors and depth of invasion, for the prediction of lymph node metastasis in EGC with a relative risk of 3.570 in high-intratumoral-LVD group compared with low-intratumoral-LVD group (P = 0.022).
  • CONCLUSION: Intratumoral LVD may be a useful, independent predictor for lymph node metastasis, especially in combination with previously established predictors in EGC.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Lymph Nodes / pathology. Lymphangiogenesis. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal / metabolism. Antibodies, Monoclonal, Murine-Derived. Antigens, CD31 / metabolism. Biomarkers, Tumor / analysis. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19777179.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


88. Sohn DK, Chang HJ, Park JW, Choi DH, Han KS, Hong CW, Jung KH, Kim DY, Lim SB, Choi HS, Jeong SY: Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol; 2007 Aug;60(8):912-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type.
  • AIMS: To evaluate the histopathological risk factors for lymph node metastasis in cases of pedunculated or semipedunculated submucosal invasive colorectal carcinoma (SICC).
  • METHODS: A total of 48 patients with non-sessile SICC who underwent systematic lymph node dissection were included.
  • RESULTS: Lymph node metastasis was observed in seven cases (14.6%).
  • Univariate analysis showed angiolymphatic invasion and tumour budding to be significantly associated with lymph node metastasis.
  • Multivariate analysis showed that tumour budding was the only independent factor associated with lymph node metastasis in cases of non-sessile SICC.
  • CONCLUSIONS: Results indicate that tumour budding is a useful risk factor for predicting lymph node metastasis in cases of pedunculated or semipedunculated SICC.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1983 Oct;7(7):613-23 [6638257.001]
  • [Cites] Int J Clin Oncol. 2006 Feb;11(1):1-8 [16508722.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):328-36 [4007423.001]
  • [Cites] Gastroenterology. 1986 Aug;91(2):419-27 [3721127.001]
  • [Cites] Prog Clin Biol Res. 1988;279:89-99 [3054934.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1052-5 [11036281.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2882-91 [12115376.001]
  • [Cites] Jpn J Clin Oncol. 2002 Oct;32(10):412-6 [12451038.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):388-91 [12749229.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1054-9 [12907899.001]
  • [Cites] Mod Pathol. 2004 May;17(5):503-11 [15001992.001]
  • [Cites] J Gastroenterol. 2004 Jun;39(6):534-43 [15235870.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):385-94 [15300569.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):832-9 [15492565.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):323-8 [1848810.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):455-61 [8261988.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1179-86 [8826938.001]
  • [Cites] Gastrointest Endosc. 1996 Nov;44(5):594-7 [8934168.001]
  • [Cites] World J Surg. 1997 Sep;21(7):694-701 [9276699.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):1032-9; discussion 1039-40 [15585391.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):92-100 [15690664.001]
  • [Cites] Gut. 1984 May;25(5):437-44 [6714785.001]
  • (PMID = 16997919.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1994481
  •  go-up   go-down


89. Vayisoglu Y, Ozcan C, Turkmenoglu O, Gorur K, Unal M, Dag A, Ocal K: Level IIb lymph node metastasis in thyroid papillary carcinoma. Eur Arch Otorhinolaryngol; 2010 Jul;267(7):1117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Level IIb lymph node metastasis in thyroid papillary carcinoma.
  • The objective of the study was to evaluate the incidence of level IIb lymph node metastases in neck dissections for thyroid papillary carcinoma (TPC) patients.
  • If level I lymph node metastasis was suspected during the procedure, level I dissection was also performed.
  • The number of dissected and metastatic lymph nodes in each specimen was recorded.
  • Twenty-two of 47 neck dissections (46.8%) were positive for the lymph node metastasis.
  • Among 47 neck dissection specimens, the incidence of lymph node metastasis at level II was 12.7% (6 of 47) and level IIb was 2.1% (1 of 47).
  • The rate of level IIb lymph node involvement among patients with metastatic cervical lymph nodes was 4.5% (1 of 22).
  • The specimen with metastatic lymph node at level IIb had also metastasis at levels IIa, III, IV, and V.
  • The results of the present study suggested that lymph node metastases in level IIb are rare in patients with TPC undergoing neck dissection.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Lymphatic Metastasis / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Prospective Studies. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054554.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Tominaga K, Nakanishi Y, Nimura S, Yoshimura K, Sakai Y, Shimoda T: Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. Dis Colon Rectum; 2005 Jan;48(1):92-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma.
  • PURPOSE: Risk factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma remain to be characterized.
  • This study examines the relationship between lymph node metastasis and clinicopathologic factors in nonpedunculated submucosal invasive colorectal carcinoma.
  • The clinicopathologic factors investigated included gender, age, tumor location, macroscopic type, tumor size, histologic type and grade, intramucosal growth pattern, lymphatic invasion, venous invasion, degree of focal dedifferentiation at the submucosal invasive front, status of the remaining muscularis mucosa, and the depth and width of submucosal invasion.
  • RESULTS: Lymph node metastases were found in 19 patients (12.3 percent).
  • Univariate analysis showed that lymphatic invasion, focal dedifferentiation at the submucosal invasive front, status of the remaining muscularis mucosa, and depth of submucosal invasion all had a significant influence on lymph node metastasis.
  • Multivariate analysis showed lymphatic invasion (P = 0.014) and high-grade focal dedifferentiation at the submucosal invasive front (P = 0.049) to be independent factors predicting lymph node metastasis.
  • No lymph node metastasis was found in tumors with a depth of submucosal invasion of <1.3 mm.
  • CONCLUSIONS: Lymphatic invasion and high-grade focal dedifferentiation at the submucosal invasive front are important predictors of lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma.
  • [MeSH-major] Carcinoma / pathology. Colorectal Neoplasms / pathology. Lymphatic Metastasis
  • [MeSH-minor] Aged. Female. Humans. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690664.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Hatano S, Kumamoto K, Ishibashi K, Ishiguro T, Ohsawa T, Okada N, Nakata H, Yokoyama M, Haga N, Ishida H: [Prediction of lateral lymph node metastasis by magnetic resonance imaging]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2297-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prediction of lateral lymph node metastasis by magnetic resonance imaging].
  • PURPOSE: Considering the advantages and disadvantages of lateral lymph node dissection in patients with advanced lower rectal cancer, it would be ideal to select candidates for lateral lymph node dissection by preoperative imaging study including magnetic resonance imaging(MRI).
  • We have reported that the cut-off value of minimal diameter of lateral lymph node could be set at 6 mm for indication of lateral lymph node dissection.
  • In the present study, we evaluated whether it would be appropriate to apply the cut-off value of minimal diameter of lateral lymph node in MRI.
  • PATIENTS AND METHODS: Forty-four patients with advanced lower rectal cancer underwent a curative surgery with lateral lymph node dissection or sampling from 1997 to 2009 in our institute.
  • RESULTS: Lateral lymph node metastasis was detected in 5 cases, one side in 4 cases and both sides in 1 case.
  • The sensitivity, specificity, positive predict value, and accuracy for predicting metastasis was 50%, 90%, 42.9% and 84.8% respectively, when the cut-off value of the minimal diameter was set at 6 mm in MRI.
  • CONCLUSIONS: Our results indicated that a 6 mm set as the cut-off value of minimal diameter of lateral lymph node was suitable for the prediction of lateral lymph node metastasis since the accuracy was relatively high (84.8%), though it was hardly to detect metastatic lymph node less than 6 mm.
  • [MeSH-major] Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224553.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Otsuji E, Kuriu Y, Ichikawa D, Ochiai T, Okamoto K, Yamagishi H: Prediction of lymph node metastasis by size of early gastric carcinoma. Hepatogastroenterology; 2007 Mar;54(74):602-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of lymph node metastasis by size of early gastric carcinoma.
  • BACKGROUND/AIMS: Tumor size requires more investigation as a factor in determining extent of regional lymph node dissection in early gastric carcinoma.
  • We retrospectively investigated 573 patients with such tumors to identify predictors of lymph node metastasis.
  • METHODOLOGY: Postoperative survival was examined for groups of patients defined by tumor size under 2 cm, between 2 and 4cm, and over than 4cm.
  • Factors predicting tumor recurrence and regional lymph node metastasis also were determined.
  • Multivariate analysis identified lymph node metastasis as a significant risk factor for recurrence of early gastric carcinoma, while identifying primary tumor size and lymphatic vessel involvement as significant risk factors for lymph node metastasis.
  • CONCLUSIONS: Lymph node metastasis, which increased risk of postoperative recurrence in early gastric carcinoma, was related to tumor size.
  • [MeSH-major] Lymphatic Metastasis / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymph Node Excision. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Risk Factors. Stomach / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523331.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


93. Tu SL, Ye ZY, Deng GL, Zhao ZS, Dong QJ, Zheng BA, Ding LP, Cao HF: [Rule of lymph node metastasis in colorectal cancer and its affecting factors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rule of lymph node metastasis in colorectal cancer and its affecting factors].
  • OBJECTIVE: To investigate the rule of lymph node metastasis in colorectal cancer and its affecting factors, and to provide clues for clinical diagnosis and treatment of colorectal cancer patients.
  • METHODS: The clinical data of 1166 cases of colorectal cancer receiving surgical resection were analyzed retrospectively.The relationships between clinicopathologic variables and lymph node metastases were evaluated by crosstabs and logistic regression in SPSS 10.0 for windows.
  • RESULTS: The rate of lymph node metastasis in colorectal cancer was 49.7%.
  • After entering crosstabs estimation, gender and tumor site were not significantly correlated with lymph node metastasis in colorectal cancer(chi2=1.46, r=0.035, P>0.05 and chi2=3.86, r=0.012, P>0.05).
  • Age, tumor size, the massive type of the tumor, the differentiating degree of the tumor, histology type and the depth of tumor invasion were proved to be independent factors influencing the lymph node metastasis in colorectal cancer (chi2 =13.1, r=0.064, P<0.05 and chi2=77.161, r=0.245, P<0.01 and chi2=144.831, r=0.341, P<0.01 and chi2=128.310, r=0.318, P<0.01 and chi2=120.418, r=0.319, P<0.01 and chi2=227.287, r=0.434, P<0.01).
  • After entering logistic regression estimation, the correlativity of risk factor of lymph node metastasis in colorectal cancer: the depth of tumor invasion > the massive type of the tumor>the differentiating degree of the tumor > tumor size.
  • Preoperative blood serum CEA level was significantly correlated with lymph node metastasis (chi2=509.599, r=0.661, P<0.01).
  • CONCLUSION: The depth of tumor invasion is the most risk factor of lymph node metastasis in colorectal cancer.
  • Preoperative high level of blood serum CEA indicates the occurrence of lymph node metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520386.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


94. Chen G, Wang Z, Liu XY, Zhang MY, Liu FY: Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma. World J Surg; 2009 Feb;33(2):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma.
  • BACKGROUND: There are few reports about abdominal lymph node metastasis of mid thoracic esophageal carcinoma.
  • This study was designed to explore the pattern of abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma and to evaluate the prognostic factors.
  • RESULTS: Abdominal lymph node metastasis occurred in 58 (15.8%) patients: 34.5% (20/58) of them were stage T1 and T2.
  • Skipping abdominal node metastasis was recognized in 13.8% (8/58) patients: all were stage T1 and T2.
  • The overall 5-year survival rate of patients with abdominal lymph node metastasis (10.3%) was lower than that of those with thoracic node metastasis (18.3%).
  • The prognosis of patients with distant abdominal lymph node metastasis was poor, and no one could survive more than 5 years.
  • Cox regression analysis showed that five or more positive nodes and distant abdominal node metastasis were independent risk factors of patients with abdominal lymph node metastasis.
  • CONCLUSIONS: Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma occurred frequently, and the surgery favorable for extensive abdominal lymph node dissection should be selected.
  • The prognosis of patients with abdominal lymph node metastasis was poor, especially those with more positive nodes and distant abdominal node metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology
  • [MeSH-minor] Abdomen / pathology. Esophagectomy / methods. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067038.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Maeda A, Chijiwa H, Sakamoto K, Miyajima Y, Umeno H, Nakashima T: [Clinical study of cervical lymph node metastasis in maxillary cancer patients]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jun;111(6):486-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of cervical lymph node metastasis in maxillary cancer patients].
  • The clinical characteristics of lymph node metastasis in maxillary cancer patients were analyzed.
  • Thirty-eight (23%) of the 166 patients who received intial treatment at Kurume University Hospital between 1978 and 2003 had cervical lymph node metastasis at the time of diagnosis.
  • The disease-specific 5-year survival rate was 63% in the lymph node metastasis negative group and 18% in the lymph node metastasis positive group (p<0.01).
  • There was a statistically significant correlation between bone invasion and lymph node metastasis in the case of the group with bone invasion of the posterior wall of the maxillary sinus.
  • Cervical neck lymph node metastasis developed in 38 (28%) of 135 posterior-wall-invasion-positive group and in none (0%) of the 31 patients in the negative group (p<0.01).
  • Because distant metastasis is common in patients with lymph node metastasis, postoperative adjuvant chemotherapy is highly recommended.
  • [MeSH-major] Lymphatic Metastasis. Maxillary Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone and Bones / pathology. Female. Humans. Male. Middle Aged. Neck. Neoplasm Invasiveness / pathology. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634455.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Min HS, Choe G, Kim SW, Park YJ, Park DJ, Youn YK, Park SH, Cho BY, Park SY: S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol; 2008 Jun;21(6):748-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid.
  • There have been few studies concerning factors predictive of lymph node metastasis in papillary microcarcinomas.
  • We analyzed the expression of S100A4, cyclin D1, p27 and MUC1, the presence of the BRAF V600E mutation and the clinicopathological features of the tumors, including patient age, tumor size (>or=5 vs <5 mm), extrathyroidal extension, multifocality, histological subtype, sclerosis and encapsulation, in a series of 198 papillary microcarcinomas in relation to lymph node metastasis to determine the predictive factors of lymph node metastasis.
  • On univariate analysis, tumor size of 5 mm or more, extrathyroidal extension, multifocality, sclerosis and the expression of S100A4 and cyclin D1 predicted lymph node metastasis, whereas patient age, expression of p27 and MUC1 and the BRAF V600E mutation did not.
  • Moreover, tumor size 5 mm or more, multifocality and expression of S100A4, especially its strong expression in the invasive fronts, were significantly associated with macrometastasis and lateral node metastasis.
  • On multivariate analysis, multifocality and expression of S100A4 were found to be common independent predictive factors of lymph node metastasis, macrometastases, and lateral node metastasis.
  • In conclusion, S100A4 expression in papillary microcarcinomas may indicate the presence of nodal metastasis.
  • Thus, S100A4 immunohistochemistry may be valuable for predicting metastatic potential in papillary microcarcinomas.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Lymphatic Metastasis / pathology. S100 Proteins / biosynthesis. Thyroid Neoplasms / pathology


97. Kunisaki C, Makino H, Kimura J, Oshima T, Fujii S, Takagawa R, Kosaka T, Ono HA, Akiyama H: Impact of lymph-node metastasis site in patients with thoracic esophageal cancer. J Surg Oncol; 2010 Jan 1;101(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymph-node metastasis site in patients with thoracic esophageal cancer.
  • BACKGROUND AND OBJECTIVES: We retrospectively compared surgical outcomes between patients with intra-thoracic and extra-thoracic (cervical and abdominal) lymph-node metastasis.
  • METHODS: The study population comprised 96 patients with lymph-node metastasis who had undergone curative esophagectomy for thoracic esophageal cancer.
  • The patients were grouped according to whether the site of lymph-node metastasis was intra-thoracic, extra-thoracic, or both intra-thoracic and extra-thoracic.
  • RESULTS: The most significant difference in disease-specific survival was detected at a threshold value of four metastatic lymph nodes.
  • Lymph-node metastasis was observed at intra-thoracic sites in 41 patients, at extra-thoracic sites in 20 patients, and at both intra-thoracic and extra-thoracic sites in 35 patients.
  • Intra-thoracic lymph-node metastasis was frequently observed in patients with middle and upper thoracic esophageal cancer.
  • There was no difference in the number of metastatic lymph nodes between patients with intra-thoracic and extra-thoracic lymph-node metastasis.
  • Multivariate analysis revealed that the number of metastatic lymph nodes was an independent prognostic factor, whereas the site of metastatic lymph nodes was not.
  • CONCLUSIONS: These findings suggest that the surgical outcomes in patients with thoracic esophageal cancer depend on the number, but not the site, of metastatic lymph nodes after curative esophagectomy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Surg Oncol. 2011 Sep 1;104(3):334; author reply 333 [21815145.001]
  • (PMID = 19921710.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Klar M, Meyer PT, Hancke K, Brink I, Orlowska-Volk M, Gitsch G, Denschlag D: Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. Anticancer Res; 2010 Sep;30(9):3787-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer.
  • BACKGROUND: In order to decrease surgery-related morbidity, we evaluated the reliability of the evaluation of lymph node metastasis in patients with uterine corpus cancer by positron-emission tomography (PET) with 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG) before surgical staging.
  • MATERIALS AND METHODS: Patients with newly diagnosed uterine corpus cancer scheduled for surgical staging, including lymphadenectomy, underwent PET imaging within 30 days before surgery.
  • PET results and postoperative histopathology were compared for each patient and each nodal site.
  • Only one patient had lymph node metastasis, which was preoperatively detected by FDG-PET scan.
  • Additionally, another patient was considered to have lymph node metastasis according to increased focal FDG uptake; however, all lymph nodes were free of malignant disease upon final pathology.
  • In contrast, all other patients without lymph node metastasis upon final pathology showed negative preoperative FDG-PET scans.
  • CONCLUSION: In patients with uterine corpus cancer, FDG-PET had an insufficient positive predictive value in detecting lymph node metastases, indicating that this method cannot replace surgical staging.
  • [MeSH-major] Lymphatic Metastasis / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography. Uterine Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944170.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


99. Chen JQ, Zhan WH, He YL, Cai SR, Peng JS, Chen ZX: [Prediction of lymph node metastasis with binary logistic regression in gastric carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Sep;8(5):436-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prediction of lymph node metastasis with binary logistic regression in gastric carcinoma].
  • OBJECTIVE: To investigate more specific markers to predict the lymph node metastasis in gastric carcinoma.
  • METHODS: The expression of heparanase mRNA was detected by reverse transcription polymerase chain reaction (RT-PCR) in 43 cases with gastric cancer.
  • Clinicopathological features influencing lymphatic metastasis such as age,sex,tumor size,tumor location, Borrmann classification, histological type, differentiation and serosal infiltration were also analyzed.
  • RESULTS: Twenty-seven cases (62.8%) in 43 gastric cancer patients had lymphatic metastasis.
  • The incidence of metastatic lymph nodes was(36.3 +/- 30.8)%.
  • Univariate analysis showed that tumor size, serosal infiltration, expressions of heparanase mRNA, CD44V6, nm23 and syndecan-1 protein were risk factors for lymph node metastasis in gastric carcinoma.
  • Multivariate analysis showed expressions of nm23 and syndecan-1 protein, serosal infiltration were independent factors for lymph node metastasis.
  • CONCLUSION: Gastric cancer with serosal infiltration, positive expressions of nm23 and syndecan-1 has greater possibility of lymph node metastasis.
  • [MeSH-major] Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Humans. Logistic Models. NM23 Nucleoside Diphosphate Kinases / metabolism. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Syndecan-1 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224662.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; 0 / Syndecan-1
  •  go-up   go-down


100. Wang HS, Liang WY, Lin TC, Chen WS, Jiang JK, Yang SH, Chang SC, Lin JK: Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum; 2005 Jun;48(6):1182-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis.
  • PURPOSE: The features of T1 colorectal adenocarcinoma and the risk determination of lymph node metastasis were reviewed.
  • Prognostic factors were assessed to verify whether the risk of lymph node metastasis would influence the long-term prognosis.
  • Patients with synchronous colorectal cancer, distant metastasis, familiar adenomatous polyposis, or inflammatory bowel disease were excluded.
  • The associations between lymph node metastasis and clinicopathologic variables were evaluated univariately using chi-squared test, Fisher's exact test, or Student's t -test, and multivariately using logistic regression.
  • Sixteen patients (10.1 percent) had lymph node metastasis.
  • The risk of lymph node metastasis included histologic grade (P = 0.005), lymphatic vessel invasion (P = 0.023), inflammation around cancer (P = 0.049), and budding at the invasive front of tumor (P = 0.022).
  • Age (P = 0.001) and number of total sampling lymph nodes (P < 0.0001) were found to be the factors influencing the overall survival.
  • CONCLUSIONS: Variables that predict lymph node metastasis in surgically resected T1 colorectal carcinoma may not impact the long-term prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793641.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement